Combination of il-4 / il-13 pathway inhibitors and plasma cell ablation for treating allergy

Abstract

To provide methods for treating an allergy, allergic reaction, or allergic disorder, for preventing or reducing the severity of an allergic reaction, or for reducing or eliminating allergen-specific serum IgE in a subject.SOLUTION: The present disclosure provides methods for treating allergy, comprising selecting a patient with an allergy and administering a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor (e.g., an anti-IL-4 receptor antibody or antigen-binding fragment thereof) in combination with a therapeutically effective amount of an agent that depletes plasma cells (e.g., an anti-BCMA / anti-CD3 bispecific antibody), wherein a plasma cell ablating agent such as an anti-BCMA / anti-CD3 bispecific antibody ablates the plasma cells, including IgE+ plasma cells, while the IL-4 / IL-13 pathway inhibitor prevents the generation of new IgE+ plasma cells, thus eliminating allergen-specific IgE in the patient.SELECTED DRAWING: None

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application was filed as a PCT International patent application on March 20, 2020, and claims priority to U.S. Provisional Patent Application No. 62 / 822,022, filed March 21, 2019, and U.S. Provisional Patent Application No. 62 / 957,550, filed January 6, 2020, the contents of each of which are incorporated by reference in their entirety herein.

[0002] The present disclosure relates to a method for treating allergy comprising administering to a subject in need of treatment a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor in combination with a therapeutically effective amount of a plasma cell depleting agent. [Background technology]

[0003] Allergies and allergic diseases are serious medical conditions with outcomes ranging from non-life-threatening reactions that resolve over time to life-threatening effects such as anaphylaxis. Allergic reactions can result from contact or exposure to a variety of products such as certain foods, insect venoms, plant-derived substances (e.g., pollen), chemicals, drugs / medications, and animal dander. The pathophysiology of allergies is influenced by a complex interplay between immunoglobulin E (IgE)-mediated sensitization, the immune system, and environmental factors. Current treatment options for allergies include avoidance, pharmacological symptomatic treatment, and prevention using allergen-specific immunotherapy (SIT). Unfortunately, these current treatment strategies are often inadequate, costly, impractical, or carry significant risks. For example, allergen avoidance is not always possible and can negatively impact the quality of life of patients and caregivers. Immunotherapeutic approaches, on the other hand, involve the intentional administration of allergens to susceptible individuals and are therefore inherently dangerous with the potential for unwanted severe allergic reactions or anaphylaxis. Summary of the Invention [Problem to be solved by the invention]

[0004] Thus, there is an unmet need in the art for new therapeutic approaches to prevent or treat allergies or allergic reactions and reduce the risk of developing an allergic reaction. [Means for solving the problem]

[0005] In one aspect, the disclosure provides a method for treating an allergy, an allergic reaction, or an allergic disorder, preventing or reducing the severity of an allergic reaction, or reducing or eliminating allergen-specific serum IgE in a subject. In some embodiments, the method comprises administering to a subject (e.g., a subject having an allergy, an allergic disorder, a mast cell activation disorder, or mastocytosis) an IL-4 / IL-13 pathway inhibitor and a plasma cell depleting agent.

[0006] In certain embodiments, the disclosure includes a method of treating allergy or preventing or reducing the severity of an allergic reaction comprising: (a) selecting a subject having an allergic disease or disorder, a mast cell activation disorder, or mastocytosis; and (b) administering to a subject in need thereof a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor and a therapeutically effective amount of a plasma cell depleting agent.

[0007] In certain embodiments, the disclosure includes a method of treating allergy or preventing or reducing the severity of an allergic reaction comprising: (a) selecting a subject having an allergic disease or disorder, a mast cell activation disorder, or mastocytosis; and (b) administering to a subject in need thereof a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor and a plasma cell depleting agent.

[0008] In certain embodiments, the disclosure includes a method for treating allergy or preventing or reducing the severity of an allergic reaction, comprising: (a) selecting a subject having an allergic disease or disorder, a mast cell activation disorder, or mastocytosis, the subject receiving a background treatment regimen including one or more doses of an IL-4 / IL-13 pathway inhibitor; and (b) administering at least one dose of a plasma cell depleting agent.

[0009] In one embodiment, administration of an IL-4 / IL-13 pathway inhibitor prevents the generation of new IgE+ plasma cells, and administration of a plasma cell depleting agent leads to the elimination of IgE+ plasma cells present in the bone marrow, thus eliminating allergen-specific serum IgE.

[0010] In certain embodiments, the present disclosure includes a method for increasing the efficacy and / or tolerability of an immunotherapy regimen in a subject with allergy. In some embodiments, the method includes administering an IL-4 / IL-13 pathway inhibitor and a plasma cell depleting agent to the subject prior to or simultaneously with the immunotherapy regimen. In some embodiments, the immunotherapy regimen is an oral immunotherapy (OIT) regimen. In some embodiments, the immunotherapy regimen is a subcutaneous immunotherapy (SCIT) regimen. In some embodiments, the immunotherapy is an allergen-specific immunotherapy regimen for a food allergen (e.g., peanut allergen). In some embodiments, the immunotherapy is an allergen-specific immunotherapy regimen for an environmental allergen.

[0011] In one embodiment of the method disclosed herein, the allergic disease or disorder is selected from the group consisting of allergic asthma, hay fever, chronic urticaria, food allergy, pollen allergy, and allergy caused by environmental allergens. In one embodiment, the subject is at risk of allergen-induced anaphylaxis. In one embodiment, the subject has seasonal allergies. In one embodiment, the subject has severe allergies. In one embodiment, the subject has allergies caused by one or more allergens selected from the group consisting of milk, dairy products, eggs, celery, sesame, wheat, meat, fruit, soybeans, fish, shellfish, sugar, peanuts, legumes, nuts, dust, dust mites, pollen, insect venom, mold, animal fur, animal dander, wool, latex, metal, household cleaners, detergents, medicines, cosmetics, perfumes, drugs such as penicillin, sulfonamides, salicylates, therapeutic monoclonal antibodies (e.g., cetuximab), ragweed, grass, and birch. In one embodiment, the allergen is contained in a food selected from the group consisting of milk, dairy products, eggs, celery, sesame, wheat, meat, fruit, soybean, fish, shellfish, sugar, peanuts, legumes, and nuts. In one embodiment, the allergen is a non-food allergen selected from the group consisting of dust, dust mites, pollen, insect venom, mold, animal fur, animal dander, wool, latex, metals, household cleaners, detergents, medicines, cosmetics, perfumes, drugs such as penicillin, sulfonamides, salicylates, therapeutic monoclonal antibodies (e.g., cetuximab), ragweed, grass, and birch.

[0012] In one embodiment of the methods disclosed herein, the IL-4 / IL-13 pathway inhibitor is selected from the group consisting of an anti-IL-4 antibody, an anti-IL-13 antibody, an anti-IL-4 / IL-13 bispecific antibody, an IL-4 receptor (IL-4R) inhibitor, an IL-4 trap, an IL-13 trap, and an anti-IL-4R antibody. The pathway inhibitor is an anti-IL-4 antibody (e.g., pascolizumab). In another embodiment, the IL-4 / IL-13 pathway inhibitor is an anti-IL-13 antibody (e.g., tralokinumab, lebrikizumab, dectrekumab, GSK679586, or MEDI7836). In another embodiment, the IL-4 / IL-13 pathway inhibitor is an anti-IL-4 / IL-13 bispecific antibody (e.g., romilkimab). In another embodiment, the IL-4 / IL-13 pathway inhibitor is an IL-4R inhibitor (e.g., an IL-4 mutein such as pitrakinra or an anti-IL-4R antibody). In another embodiment, the IL-4 / IL-13 pathway inhibitor is an anti-IL-4R antibody. In another embodiment, the IL-4 / IL-13 pathway inhibitor is an IL-4 trap or an IL-13 trap.

[0013] In one embodiment, the IL-4 / IL-13 pathway inhibitor is an anti-IL-4R antibody or an antigen-binding fragment thereof. In one embodiment, the anti-IL-4R antibody comprises a heavy chain variable region (HCVR) comprising three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2 and HCDR3), and a light chain variable region (LCVR) comprising three light chain CDRs (LCDR1, LCDR2 and LCDR3), where: HCDR1 has the amino acid sequence of SEQ ID NO:3; HCDR2 has the amino acid sequence of SEQ ID NO:4; HCDR3 has the amino acid sequence of SEQ ID NO:5; LCDR1 has the amino acid sequence of SEQ ID NO:6; LCDR2 has the amino acid sequence of SEQ ID NO:7; LCDR3 has the amino acid sequence of SEQ ID NO:8. In another embodiment, the anti-IL-4R antibody comprises a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:1 and a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:2. In another embodiment, the anti-IL-4R antibody comprises a heavy chain and a light chain, wherein the heavy chain has the amino acid sequence of SEQ ID NO: 9. In another embodiment, the anti-IL-4R antibody comprises a heavy chain and a light chain, wherein the light chain has the amino acid sequence of SEQ ID NO: 10. In another embodiment, the anti-IL-4R antibody comprises a heavy chain and a light chain, wherein the heavy chain has the amino acid sequence of SEQ ID NO: 9 and the light chain has the amino acid sequence of SEQ ID NO: 10. In another embodiment, the IL-4 / IL-13 pathway inhibitor is dupilumab or a biological equivalent thereof. In another embodiment, the IL-4 / IL-13 pathway inhibitor is selected from the group consisting of dupilumab, pascolizumab, AMG317, MEDI2045, MEDI9314, tralokinumab, lebricizumab, anrukinzumab, dextrekumab, GSK679586, MEDI7836, romilkimab, IL-4 trap, IL-13 trap, AER-003, and pitrakinra.

[0014] In one embodiment of the methods disclosed herein, the plasma cell depleting agent is selected from the group consisting of a B cell maturation antigen (BCMA) targeting agent, a proteasome inhibitor, a histone deacetylase inhibitor, a B cell activating factor (BAFF) inhibitor, and an inhibitor of proliferation-inducing ligand (APRIL; CD256). In one embodiment, the BCMA targeting agent is selected from the group consisting of an anti-BCMA / anti-CD3 bispecific antibody, a chimeric antigen receptor to BCMA, and an anti-BCMA antibody conjugated to a cytotoxic drug.

[0015] In one embodiment, the plasma cell depleting agent is an anti-BCMA / anti-CD3 bispecific antibody or antigen-binding fragment thereof, comprising (a) a first antigen-binding domain that specifically binds BCMA; and (b) a second antigen-binding domain that specifically binds CD3. In one embodiment, the first antigen-binding domain comprises three heavy chain CDRs (HCDR1, HCDR2 and HCDR3) comprised together with a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 12; and three light chain CDRs (LCDR1, LCDR2 and LCDR3) comprised together with a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 20. In a further embodiment, HCDR1 has the amino acid sequence of SEQ ID NO: 14; HCDR2 has the amino acid sequence of SEQ ID NO: 16; HCDR3 has the amino acid sequence of SEQ ID NO: 18; LCDR1 has the amino acid sequence of SEQ ID NO: 22; LCDR2 has the amino acid sequence of SEQ ID NO: 24; and LCDR3 has the amino acid sequence of SEQ ID NO: 26. In another embodiment, the first antigen-binding domain comprises three heavy chain CDRs (HCDR1, HCDR2 and HCDR3) comprised together with a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 12; and three light chain CDRs (LCDR1, LCDR2 and LCDR3) comprised together with a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 20. In a further embodiment, HCDR1 has the amino acid sequence of SEQ ID NO: 14; HCDR2 has the amino acid sequence of SEQ ID NO: 16; HCDR3 has the amino acid sequence of SEQ ID NO: 18; LCDR1 has the amino acid sequence of SEQ ID NO: 22; LCDR2 has the amino acid sequence of SEQ ID NO: 24; and LCDR3 has the amino acid sequence of SEQ ID The two antigen-binding domains comprise three heavy chain CDRs (HCDR1, HCDR2 and HCDR3) comprised together with a heavy chain variable region (HCVR) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 28 and 36; and three light chain CDRs (LCDR1, LCDR2 and LCDR3) comprised together with a light chain variable region (LCVR) comprising an amino acid sequence of SEQ ID NO: 20. In a further embodiment, HCDR1 has the amino acid sequence of SEQ ID NO: 30 or 38; HCDR2 has the amino acid sequence of SEQ ID NO: 32 or 40; HCDR3 has the amino acid sequence of SEQ ID NO: 34 or 42; LCDR1 has the amino acid sequence of SEQ ID NO: 22; LCDR2 has the amino acid sequence of SEQ ID NO: 24; and LCDR3 has the amino acid sequence of SEQ ID NO: 26. In one embodiment, the anti-BCMA / anti-CD3 bispecific antibody comprises: (a) a first antigen binding domain which specifically binds BCMA and comprises three heavy chain CDRs and three light chain CDRs, where the six CDRs, HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3, comprise the amino acid sequences of SEQ ID NOs: 14-16-18-22-24-26; and (b) a second antigen binding domain which specifically binds CD3 and comprises three heavy chain CDRs and three light chain CDRs, where the six CDRs, HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3, comprise the amino acid sequences of SEQ ID NOs: 30-32-34-22-24-26. In one embodiment, the anti-BCMA / anti-CD3 bispecific antibody comprises: (a) a first antigen-binding domain which specifically binds BCMA and comprises three heavy chain CDRs and three light chain CDRs, where the six CDRs, HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3, comprise the amino acid sequences of SEQ ID NOs: 14-16-18-22-24-26; and (b) a second antigen-binding domain which specifically binds CD3 and comprises three heavy chain CDRs and three light chain CDRs, where the six CDRs, HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3, comprise the amino acid sequences of SEQ ID NOs: 38-40-42-22-24-26.In one embodiment, the anti-BCMA / anti-CD3 bispecific antibody comprises: (a) a first antigen-binding domain comprising an HCVR of SEQ ID NO: 12 and an LCVR of SEQ ID NO: 20; and (b) a second antigen-binding domain comprising an HCVR of SEQ ID NO: 28 and an LCVR of SEQ ID NO: 20. In one embodiment, the anti-BCMA / anti-CD3 bispecific antibody comprises: (a) a first antigen-binding domain comprising an HCVR of SEQ ID NO: 12 and an LCVR of SEQ ID NO: 20; and (b) a second antigen-binding domain comprising an HCVR of SEQ ID NO: 36 and an LCVR of SEQ ID NO: 20.

[0016] In one embodiment, the IL-4 / IL-13 pathway inhibitor is administered prior to the plasma cell depleting agent. In one embodiment, the IL-4 / IL-13 pathway inhibitor is administered after the plasma cell depleting agent. In one embodiment, administration of the IL-4 / IL-13 pathway inhibitor in combination with the plasma cell depleting agent blocks IgE production and eliminates allergen-specific IgE from the serum of patients compared to subjects treated with either therapeutic agent as monotherapy.

[0017] In another embodiment, one or more doses of an IL-4 / IL-13 pathway inhibitor are administered in combination with one or more doses of a plasma cell depleting agent. In another embodiment, at least one dose of an IL-4 / IL-13 pathway inhibitor comprises about 0.1 to about 50 mg per kg of the subject's body weight. In another embodiment, at least one dose of an IL-4 / IL-13 pathway inhibitor comprises about 0.05 to about 600 mg of inhibitor. In another embodiment, at least one dose of a plasma cell depleting agent comprises about 0.1 mg to about 20 mg per kg of the subject's body weight. In another embodiment, at least one dose of a plasma cell depleting agent comprises about 0.05 to about 500 mg of agent.

[0018] In another embodiment, the method further comprises administering at least one additional therapeutic agent or therapy. In another embodiment, the additional therapeutic agent or therapy is an IgE antagonist, an antihistamine, an anti-inflammatory agent, a corticosteroid, a leukotriene antagonist, a mast cell inhibitor, a bronchodilator, a decongestant, an epinephrine, an IL-1 antagonist, or a combination thereof. antagonist, IL-5 antagonist, IL-31 antagonist, IL-33 antagonist, IL-25 antagonist, interferon gamma, TNF antagonist, and / or TSLP antagonist.

[0019] In one aspect, the disclosure provides pharmaceutical compositions and combinations for treating allergies, allergic reactions or allergic disorders in subjects with allergies, preventing or reducing the severity of allergic reactions, reducing or eliminating allergen-specific serum IgE in a subject, or enhancing the efficacy and / or tolerability of an immunotherapeutic regimen. In some embodiments, the pharmaceutical composition or combination comprises an IL-4 / IL-13 pathway inhibitor (e.g., an anti-IL-4Rα antibody) and a plasma cell depleting agent (e.g., a BCMA targeting agent). In some embodiments, the pharmaceutical composition or combination comprises a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor (e.g., an anti-IL-4Rα antibody) and a therapeutically effective amount of a plasma cell depleting agent (e.g., a BCMA targeting agent). In some embodiments, the pharmaceutical composition or combination comprises a subtherapeutic dose of an IL-4 / IL-13 pathway inhibitor (e.g., an anti-IL-4Rα antibody) and / or a plasma cell depleting agent (e.g., a BCMA targeting agent).

[0020] In yet another aspect, the disclosure provides for the use of an IL-4 / IL-13 pathway inhibitor (e.g., an anti-IL-4Rα antibody) and a plasma cell depleting agent (e.g., a BCMA targeting agent) in the manufacture of a medicament for treating an allergy, allergic reaction, or allergic disorder in an allergic subject, preventing or reducing the severity of an allergic reaction, reducing or eliminating allergen-specific serum IgE in a subject, or increasing the efficacy and / or tolerability of an immunotherapeutic regimen. In some embodiments, one or both of the IL-4 / IL-13 pathway inhibitor and the plasma cell depleting agent are used in a therapeutically effective amount. In some embodiments, one or both of the IL-4 / IL-13 pathway inhibitor and the plasma cell depleting agent are used in a subtherapeutic dose. [Brief description of the drawings]

[0021] [Figure 1] FIG. 1 is a schematic diagram of the house dust mite (HDM) exposure and antibody treatment protocol according to the study described in Example 1. [Figure 2A] Figure 2A shows serum IgE levels in mice exposed to HDM for 11 weeks followed by 1 week of rest and treated with either saline, no antibody, isotype control antibody, REGN5459 (anti-BCMA x anti-CD3 bispecific antibody), REGN1103 (anti-IL-4R antibody), or a combination of REGN5459 and REGN1103 according to the study described in Example 1. Asterisks (*) indicate the degree of statistical significance compared to the isotype control (IgG). [Figure 2B] Figure 2B shows serum IgE levels in mice exposed to HDM for 11 weeks followed by 6 weeks of rest and treated with either saline, no antibody, isotype control antibody, REGN5459 (anti-BCMA x anti-CD3 bispecific antibody), REGN1103 (anti-IL-4R antibody), or a combination of REGN5459 and REGN1103 according to the study described in Example 1. Asterisks (*) indicate the degree of statistical significance compared to the isotype control (IgG). [Diagram 3]FIG. 3 is a schematic diagram of the HDM exposure and antibody treatment protocol according to the study described in Example 2. [Figure 4A] Figure 4A shows HDM-specific serum IgE levels in mice after one week of continued exposure to HDM and treatment with anti-BCMA x anti-CD3 bispecific antibody (REGN5459) or isotype control (REGN4460) according to the study described in Example 2. Asterisks (*) indicate the degree of statistical significance compared to the isotype control (IgG). LLOQ = lower limit of quantification. [Figure 4B] Figure 4B shows HDM-specific serum IgE levels in mice after 3 weeks of continued exposure to HDM and treatment with anti-BCMA x anti-CD3 bispecific antibody (REGN5459) or isotype control (REGN4460) according to the study described in Example 2. Asterisks (*) indicate the degree of statistical significance compared to the isotype control (IgG). [Figure 4C] Figure 4C shows HDM-specific serum IgE levels in mice after 5 weeks of continued exposure to HDM and treatment with anti-BCMA x anti-CD3 bispecific antibody (REGN5459) or isotype control (REGN4460) according to the study described in Example 2. Asterisks (*) indicate the degree of statistical significance compared to the isotype control (IgG). [Diagram 5] Figure 5 shows the effect of anti-BCMA x anti-CD3 bispecific antibody and anti-IL-4Rα antibody alone or in combination on IgE bone marrow plasma cells 5 weeks after administration of anti-BCMA x anti-CD3 bispecific antibody. Asterisks (*) indicate the degree of statistical significance compared to isotype control (IgG); *p≦0.05; **p≦0.01; ***p≦0.001; ****p≦0.0001. [Figure 6] FIG. 6 is a schematic diagram of the HDM exposure and antibody treatment protocol according to the study described in Example 4. [Figure 7]Figure 7 shows the effect of anti-BCMA x anti-CD3 bispecific antibody and anti-IL-4Rα antibody alone or in combination on serum HDM-specific IgE levels. Treatment groups are described in Example 4 and Table 7 and are: Group A (saline), Group B (12 weeks HDM, no antibody), Group C (15 weeks HDM, no antibody), Group D (15 weeks HDM, isotype control antibody), Group E (15 weeks HDM, anti-BCMA x anti-CD3 bispecific antibody), Group F (15 weeks HDM, anti-IL-4Rα antibody), and Group G (15 weeks HDM, anti-IL-4Rα antibody and anti-BCMA x anti-CD3 bispecific antibody). Statistical significance is compared between treatment groups as shown in the inset. ns = not statistically significant; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001. LLOQ = lower limit of quantification. [Figure 8A] Figures 8A-8D show the effect of anti-BCMA x anti-CD3 bispecific antibody alone or in combination with anti-IL-4Rα antibody on total bone marrow plasma cells (Figure 8A), IgE bone marrow plasma cells (Figure 8B), total spleen plasma cells (Figure 8C), and IgE spleen plasma cells (Figure 8D). Treatment groups are described in Example 4 and Table 7 and are: Group A (saline), Group B (12 weeks HDM, no antibody), Group C (15 weeks HDM, no antibody), Group D (15 weeks HDM, isotype control antibody), Group E (15 weeks HDM, anti-BCMA x anti-CD3 bispecific antibody), Group F (15 weeks HDM, anti-IL-4Rα antibody), and Group G (15 weeks HDM, anti-IL-4Rα antibody and anti-BCMA x anti-CD3 bispecific antibody). Statistical significance is compared between treatment groups as shown in the inset. ns=not statistically significant; *p≦0.05; **p≦0.01; ***p≦0.001; ****p≦0.0001. [Figure 8B]Figures 8A-8D show the effect of anti-BCMA x anti-CD3 bispecific antibody alone or in combination with anti-IL-4Rα antibody on total bone marrow plasma cells (Figure 8A), IgE bone marrow plasma cells (Figure 8B), total spleen plasma cells (Figure 8C), and IgE spleen plasma cells (Figure 8D). Treatment groups are described in Example 4 and Table 7 and are: Group A (saline), Group B (12 weeks HDM, no antibody), Group C (15 weeks HDM, no antibody), Group D (15 weeks HDM, isotype control antibody), Group E (15 weeks HDM, anti-BCMA x anti-CD3 bispecific antibody), Group F (15 weeks HDM, anti-IL-4Rα antibody), and Group G (15 weeks HDM, anti-IL-4Rα antibody and anti-BCMA x anti-CD3 bispecific antibody). Statistical significance is compared between treatment groups as shown in the inset. ns=not statistically significant; *p≦0.05; **p≦0.01; ***p≦0.001; ****p≦0.0001. [Figure 8C] Figures 8A-8D show the effect of anti-BCMA x anti-CD3 bispecific antibody alone or in combination with anti-IL-4Rα antibody on total bone marrow plasma cells (Figure 8A), IgE bone marrow plasma cells (Figure 8B), total spleen plasma cells (Figure 8C), and IgE spleen plasma cells (Figure 8D). Treatment groups are described in Example 4 and Table 7 and are: Group A (saline), Group B (12 weeks HDM, no antibody), Group C (15 weeks HDM, no antibody), Group D (15 weeks HDM, isotype control antibody), Group E (15 weeks HDM, anti-BCMA x anti-CD3 bispecific antibody), Group F (15 weeks HDM, anti-IL-4Rα antibody), and Group G (15 weeks HDM, anti-IL-4Rα antibody and anti-BCMA x anti-CD3 bispecific antibody). Statistical significance is compared between treatment groups as shown in the inset. ns=not statistically significant; *p≦0.05; **p≦0.01; ***p≦0.001; ****p≦0.0001. [Figure 8D]Figures 8A-8D show the effect of anti-BCMA x anti-CD3 bispecific antibody alone or in combination with anti-IL-4Rα antibody on total bone marrow plasma cells (Figure 8A), IgE bone marrow plasma cells (Figure 8B), total spleen plasma cells (Figure 8C), and IgE spleen plasma cells (Figure 8D). Treatment groups are described in Example 4 and Table 7 and are: Group A (saline), Group B (12 weeks HDM, no antibody), Group C (15 weeks HDM, no antibody), Group D (15 weeks HDM, isotype control antibody), Group E (15 weeks HDM, anti-BCMA x anti-CD3 bispecific antibody), Group F (15 weeks HDM, anti-IL-4Rα antibody), and Group G (15 weeks HDM, anti-IL-4Rα antibody and anti-BCMA x anti-CD3 bispecific antibody). Statistical significance is compared between treatment groups as shown in the inset. ns=not statistically significant; *p≦0.05; **p≦0.01; ***p≦0.001; ****p≦0.0001. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0022] It is to be understood that this disclosure is not limited to the particular methods and experimental conditions described, as such methods and conditions may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, and the scope of the disclosure will be limited only by the appended claims.

[0023] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this disclosure belongs.As used herein, the term "about" when used in relation to a specific listed value means that the value can vary by 1% or less from the listed value.For example, as used herein, the expression "about 100" includes 99 and 101, and all values ​​therebetween (for example, 99.1, 99.2, 99.3, 99.4, etc.).

[0024] Although any methods and materials similar or equivalent to those described herein can be used in the practice of this disclosure, the preferred methods and materials are now described.

[0025] Introduction Allergic symptoms, including anaphylaxis, are caused by allergen-induced cross-linking of allergen-specific IgE bound to FcεR on effector cells (mast cells and basophils), which can induce mast cell degranulation. In allergic individuals, circulating IgE originates from antibody-secreting cells in the bone marrow and from B cells that class-switch to produce new IgE-producing cells. Antibody-secreting cells that accumulate in the bone marrow are long-lived and provide a source of allergen-specific IgE even in the absence of allergens. Furthermore, allergen-specific IgE can be long-lived in individuals, as evidenced at least by the following: (1) IgE is maintained in atopic patients in the absence of allergens (Luger et al., Allergol Int 2010, 59:1-8); (2) allergy can be transferred from atopic patients to nonatopic individuals upon bone marrow transplantation from the former to the latter (Garzor et al., Allergol Int 2010, 59:1-8); z et al., J Eur Acad Dermatol Venereol 2016,30:1136-1139; Hallstrand et al., Blood 2004,104:3086-3090); and (3) serum IgE does not disappear in patients with IgE+ B cell depletion approaches (Gauvreau et al., Sci Transl Med 2014,6:243ra85).

[0026] In earlier studies, the inventors of the present disclosure observed that treatment with anti-IL-4R antibodies prevents class switching and differentiation of B cells into IgE-producing plasma cells in a mouse model of allergen-induced pulmonary inflammation, but does not affect IgE+ plasma cells in the bone marrow during chronic allergen exposure. Thus, the inventors hypothesized that treatment with an IL-4 / IL-13 pathway inhibitor combined with targeted removal of long-lived plasma cells (including IgE+ plasma cells) could lead to blocking of IgE production from newly generated IgE+ plasma cells as well as IgE+ plasma cells in the bone marrow. As shown herein, this combination of treatments can significantly reduce or completely block the production of allergen-specific IgE in an animal model of allergen (HDM)-induced type 2 pulmonary inflammation. Thus, such a combination of therapeutic agents may also be useful for the treatment of allergic diseases in atopic subjects.

[0027] How to Treat Allergies In one aspect, the present disclosure relates to surprising results obtained by the inventors that administration of an IL-4 / IL-13 pathway inhibitor (e.g., an anti-IL-4R antibody) in combination with a plasma cell depleting agent (e.g., an anti-BCMA / anti-CD3 bispecific antibody) in a chronic allergen-induced pulmonary inflammation model resulted in complete elimination of allergen-specific IgE in the serum of subjects.

[0028] Thus, in some embodiments, the disclosure provides a method for treating, ameliorating, or reducing the severity of at least one allergic symptom or sign in a subject. In some embodiments, the disclosure provides a method for preventing or reducing the severity of an allergic reaction in a subject. In one aspect, the disclosed method includes selecting a subject having an allergic disease or disorder, a mast cell activation disorder, or mastocytosis, and administering to the subject in need thereof a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor (e.g., an anti-IL-4 antibody, an anti-IL-13 antibody, an anti-IL-4 / IL-13 bispecific antibody, an IL-4 receptor (IL-4R) inhibitor, an anti-IL-4R antibody, or other "IL-4 / IL-13 pathway inhibitor" as described herein) and a therapeutically effective amount of a plasma cell depleting agent (e.g., an anti-BCMA / anti-CD3 bispecific antibody, or other "plasma cell depleting agent" as described herein).

[0029] In this disclosure, reference to any particular anti-IL-4R antibody and / or any particular plasma cell depleting agent is provided to describe a representative IL-4 / IL-13 pathway inhibitor and a representative plasma cell depleting agent, respectively, and does not limit the scope of the disclosure, as other combinations of IL-4 / IL-13 pathway inhibitors and plasma cell depleting agents may also be used.

[0030] As used herein, the terms "treat", "therapeutic" and the like refer to relieving allergic symptoms in a subject, eliminating the cause of allergic symptoms either temporarily or permanently, or preventing or delaying the onset of allergic symptoms. The terms as used herein also include reducing or neutralizing allergen-specific serum IgE to prevent an allergic reaction. In some embodiments, these terms refer to a reduction in serum allergen-specific IgE levels of at least 50%, 60%, 70%, 80% or more compared to baseline upon administration of an IL-4 / IL-13 pathway inhibitor in combination with a plasma cell depleting agent provided by the methods of the present disclosure. In certain embodiments, In this context, these terms refer to a reduction in serum allergen-specific IgE levels compared to baseline upon administration of an IL-4 / IL-13 pathway inhibitor in combination with a plasma cell depleting agent provided by the methods of the present disclosure.

[0031] As used herein, the phrase "subject in need thereof" refers to a human or non-human animal exhibiting one or more symptoms or signs of allergy or atopy and / or diagnosed with allergy to an allergen. The terms "subject" and "patient" are used interchangeably herein. In certain embodiments, the term "subject in need thereof" includes a subject at high risk of developing allergy or an allergic reaction to an allergen. In certain embodiments, the term includes a subject exhibiting allergen sensitization to one or more allergens. In certain embodiments, the methods of the present disclosure may be used to treat a subject exhibiting elevated levels of one or more serum biomarkers, including, but not limited to, total IgE, allergen-specific IgE, thymus and activation-regulated chemokine (TARC), lung and activation-regulated chemokine (PARC), lactate dehydrogenase (LDH), and / or periostin. For example, in some embodiments, the methods of the disclosure comprise administering to a patient with elevated levels of allergen-specific serum IgE an IL-4 / IL-13 pathway inhibitor in combination with a plasma cell depleting agent.

[0032] The term "subject in need thereof" also includes subjects with an allergic disease or disorder selected from the group consisting of allergic asthma, hay fever, chronic urticaria, food allergies, pollen allergies, and allergies due to environmental (non-food) allergens. The term also includes subjects suffering from severe allergies due to one or more allergens. For example, in some embodiments, a subject has a "severe" allergy if the subject exhibits one or more severe symptoms of an allergic reaction, such as symptoms of anaphylaxis (e.g., difficulty breathing / wheezing, swollen tongue, swollen / tight throat, difficulty speaking and / or hoarseness, wheezing or persistent cough, nausea / vomiting, persistent dizziness, collapse, or loss of consciousness).

[0033] In certain embodiments, the term "subject in need thereof" includes subjects who are susceptible to allergic reactions or at high risk of developing an allergic reaction to an allergen. For example, the term includes subjects who are at risk of anaphylaxis due to an allergen such as peanut or penicillin. In certain embodiments, a subject may be at high risk of developing an allergy or an allergic reaction to an allergen due to sensitization to said allergen. For example, the term includes subjects who exhibit an increased level of serum IgE specific to one or more allergens, such as one or more food allergens and / or environmental allergens ("allergen sensitization"). In some embodiments, the subject has an allergen-specific IgE level of at least about 0.35 kU / L (e.g., for one or more allergens disclosed herein, such as a food allergen or an environmental allergen, or an allergen selected from the group consisting of milk, dairy products, eggs, celery, sesame, wheat, meat, fruit, soybean, fish, shellfish, sugar, peanuts, legumes, nuts, dust, dust mites, pollen, insect venom, mold, animal fur, animal dander, wool, latex, metals, household cleaners, detergents, medicines, cosmetics, perfumes, pharmaceuticals such as penicillin, sulfonamides, salicylates, therapeutic monoclonal antibodies, ragweed, grass, and birch). In the context of this disclosure, the term "subject in need thereof" also includes a subject having an atopic disease, and a subject having a disease or disorder selected from the group consisting of atopic dermatitis, asthma, allergic rhinitis, eosinophilic esophagitis, and food allergy. The term "subject" also includes subjects with elevated levels of serum total IgE and allergen-specific IgE, or serum chemokines (e.g., CCL17 or CCL27), who may be at increased risk of developing an allergic reaction. In one aspect, the disclosure provides a method for reducing the risk of developing an allergy or allergic reaction in a susceptible subject.

[0034] As used herein, the terms "allergic response", "allergic reaction", "allergic symptoms" and the like include one or more signs or symptoms selected from the group consisting of urticaria (e.g., rash), angioedema, rhinitis, asthma, vomiting, sneezing, runny nose, sinusitis, watery eyes, wheezing, bronchospasm, reduced peak expiratory flow (PEF), gastrointestinal disorders, flushing, swollen lips, swollen tongue, reduced blood pressure, anaphylaxis, and organ dysfunction / failure. "Allergic response", "allergic reaction", "allergic symptoms" and the like also include immunological responses and reactions, such as, for example, increased IgE production and / or increased allergen-specific immunoglobulin production.

[0035] The term "allergen" as used herein includes any substance, chemical, particle or composition that can stimulate an allergic reaction in a susceptible individual. Allergens can be contained in or derived from foods such as, for example, dairy products (e.g., milk), eggs, celery, sesame, wheat, meat, soybeans, fish, shellfish, sugars (e.g., sugars present in meat such as alpha-galactose), peanuts, other legumes (e.g., beans, peas, soybeans, etc.), and nuts; allergens contained in or derived from foods are referred to herein as "food allergens." Alternatively, the allergen may be contained in or derived from non-food substances, such as, for example, dust (including, for example, dust mites), pollen, insect venom (e.g., venom of bees, wasps, mosquitoes, fire ants, etc.), mold, animal fur, animal dander, wool, latex, metals (e.g., nickel), household cleaners, detergents, medicines, cosmetics (e.g., perfumes, etc.), drugs (e.g., penicillin, sulfonamides, salicylates, etc.), therapeutic monoclonal antibodies (e.g., cetuximab), indoor or outdoor environmental allergens such as ragweed, grasses and birch. Exemplary pollen allergens include, for example, birch pollen, cedar pollen, oak pollen, alder pollen, hornbeam pollen, Aeschylus pollen, willow pollen, poplar pollen, Plantanus pollen, Tilia pollen, Olea pollen, Ash juniper pollen, and Alstonia scolarii. Other examples of allergens can be found elsewhere herein.

[0036] The present disclosure includes a method for treating allergy, including severe allergy, or for preventing or reducing the severity of an allergic reaction, comprising administering to a subject in need thereof a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor (e.g., an anti-IL-4R antibody described herein) in combination with a therapeutically effective amount of a plasma cell depleting agent (e.g., an anti-BCMA x anti-CD3 bispecific antibody described herein). In some embodiments, the disclosed methods target an allergic disease or disorder, a mast cell activation disorder, or mastocytosis. In one embodiment, the allergic disease or disorder is selected from the group consisting of allergic asthma, hay fever, chronic urticaria, food allergy, pollen allergy, and allergy due to environmental (non-food) allergens. In some embodiments, the allergic disease is a food allergy, e.g., a peanut allergy. In some embodiments, the allergic disease is a severe food allergy.

[0037] According to certain embodiments, the present disclosure includes a method of treating allergy or preventing or reducing the severity of an allergic reaction, comprising: (a) selecting a patient having an allergic disease or disorder, a mast cell activation disorder, or mastocytosis, the patient receiving a background treatment regimen including one or more doses of an IL-4 / IL-13 pathway inhibitor; and (b) administering at least one dose of a plasma cell depleting agent. In this aspect, the method enhances the therapeutic effect of the IL-4 / IL-13 pathway inhibitor in reducing serum levels of allergen-specific IgE. Certain embodiments In the method, a patient is receiving a therapeutic regimen that includes one or more doses of an IL-4 / IL-13 pathway inhibitor and is administered one or more doses of a plasma cell depleting agent, thereby enhancing the anti-allergic effect of the IL-4 / IL-13 pathway inhibitor.

[0038] In some embodiments, the disclosed methods include administering a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor and a therapeutically effective amount of a plasma cell depleting agent in combination with an additional therapeutic agent or therapy (e.g., regimen or procedure). The additional therapeutic agent or therapy may be administered to enhance the anti-allergic effect, to reduce the toxic effect of one or more therapies, and / or to reduce the dosage of one or more therapies. In various embodiments, the additional therapeutic agent or therapy may include one or more IgE antagonists, antihistamines, anti-inflammatory drugs, corticosteroids, leukotriene antagonists, mast cell inhibitors, bronchodilators, decongestants, epinephrine, IL-1 antagonists, IL-5 antagonists, IL-31 antagonists, IL-33 antagonists, IL-25 antagonists, interferon gamma, TNF antagonists, and TSLP antagonists.

[0039] The additional therapeutic agent may be, for example, another IL-4R antagonist, an IL-1 antagonist (including, for example, the IL-1 antagonists described in U.S. Pat. No. 6,927,044), an IL-6 antagonist, an IL-6R antagonist (including, for example, the anti-IL-6R antibodies described in U.S. Pat. No. 7,582,298), an IL-13 antagonist, a tumor necrosis factor (TNF) antagonist, an IL-8 antagonist, an IL-9 antagonist, an IL-17 antagonist, an IL-5 antagonist, an IgE antagonist (e.g., an anti-IgE antibody such as omalizumab), a CD48 The antagonist may be an IL-31 antagonist (including, for example, those described in U.S. Patent No. 7,531,637), a thymic stromal lymphopoietin (TSLP) antagonist (including, for example, those described in U.S. Patent No. 2011 / 027468), interferon-gamma (IFNγ), an antibiotic, a topical corticosteroid, tacrolimus, pimecrolimus, cyclosporine, azathioprine, methotrexate, cromolyn sodium, a proteinase inhibitor, a systemic corticosteroid, a systemic immunotherapy, an antihistamine, or a combination thereof.

[0040] In certain embodiments, the disclosed methods of administering a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor and a therapeutically effective amount of a plasma cell depleting agent lead to a reduction or suppression of one or more allergic symptoms or indications compared to untreated subjects or subjects treated with either inhibitor as monotherapy.

[0041] In certain embodiments, the disclosed methods lead to a reduction, preferably complete elimination, of allergen-specific IgE in treated subjects. For example, the disclosed methods of administering a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor and a therapeutically effective amount of a plasma cell depleting agent promote at least about 50%, about 60%, about 70%, or about 80% or more reduction in serum levels of allergen-specific IgE in treated subjects compared to untreated subjects or subjects treated with either inhibitor as monotherapy. In certain embodiments, the disclosed methods lead to complete elimination of allergen-specific serum IgE in treated subjects compared to subjects treated with either agent as monotherapy.

[0042] According to certain embodiments, a subject may exhibit a decrease in the level of serum IgE specific for one or more allergens after administration of one or more doses of an IL-4 / IL-13 pathway inhibitor (e.g., an anti-IL-4R antibody) in combination with one or more doses of a plasma cell depleting agent (e.g., an anti-BCMA / anti-CD3 bispecific antibody). For example, a subject may exhibit a decrease in the level of serum IgE specific for one or more allergens after administration of one or more doses of an anti-IL-4R antibody (e.g., dupilumab) in combination with a plasma cell depleting agent on about day 8, day 15, day 22, day 25, day 29, day 36, day 4, day 5, day 6, day 7, day 8, day 9, day 10, day 11, day 12, day 13, day 14, day 15, day 16, day 17, day 18, day 19, day 20, day 21, day 22, day 23, day 24, day 25, day 26, day 27, day 28, day 29, day 30, day 31, day 32, day 33, day 34, day 35, day 36, day 37, day 38, day 39, day 40, day 41, day 42, day 43, day 44, day 45, day 46, day 47, day 48, day 49, day 50, day 51, day 52, day 53, day 54, day 55, day 56, day 57, day 58, day 59, day 60, day 61, day 62, day 63, day 64, day 65, day 66, day 67, day On day 3, 50, 57, 64, 71, 85, or 112, according to the present disclosure, the subject may show about a 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or more decrease in allergen-specific IgE from baseline (wherein "baseline" is defined as the level of allergen-specific IgE in the subject immediately prior to the first administration).

[0043] Methods for detecting and / or quantitating allergen-specific or total IgE in serum are known in the art; kits for measuring such are available from a variety of commercial sources; and various commercial diagnostic laboratories offer services to provide measurement of such levels as well.

[0044] For example, Phadiatope™ is a commercially available variant of a serum-specific or antigen-specific IgE assay test introduced for screening allergic sensitization (Merrett et al., 1987, Allergy 17:409-416). This test provides a simultaneous test of serum-specific IgE against a mixture of related allergens that cause common inhalant allergies. This test gives a qualitative result, positive or negative, depending on the fluorescent response obtained. A positive test result is indicated if the patient sample gives a fluorescent response equal to or greater than the reference. A patient sample with a low fluorescent response is indicated a negative test result. The present disclosure includes a method comprising selecting a subject showing a positive test result and administering to the subject a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor in combination with a plasma cell depleting agent.

[0045] In certain embodiments, the combination of therapeutic agents administered is safe and well-tolerated by the subject, such that there is no increase in adverse side effects compared to subjects treated with either therapeutic agent as a monotherapy.

[0046] IL-4 / IL-13 pathway inhibitors The methods disclosed herein include administering a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor to a subject in need thereof. As used herein, an "IL-4 / IL-13 pathway inhibitor" (also referred to herein as an "IL-4 / IL-13 pathway antagonist", "IL-4 / IL-13 pathway blocker", etc.) is any agent that inhibits or attenuates at least one of the following: (i) the binding of IL-4 and / or IL-13 to their respective receptors; (ii) the signaling and / or activity of IL-4 and / or IL-13; and / or (iii) downstream signaling / activity resulting from the binding of IL-4 and / or IL-13 to their respective receptors. Exemplary IL-4 / IL-13 pathway inhibitors include anti-IL-4 antibodies (e.g., those disclosed in U.S. Pat. No. 7,740,843, and U.S. Patent Application Publication Nos. 2010 / 0297110 and 2016 / 0207995), anti-IL-13 antibodies (e.g., those disclosed in U.S. Pat. Nos. 7,501,121, 7,674,459, 7,807,788, 7,910,708, 7,915,388, 7,935,343, 8,088,618, 8,691,233, and 9,605,065), and / or anti-IL-13 antibodies (e.g., those disclosed in U.S. Pat. Nos. 7,501,121, 7,674,459, 7,807,788, 7,910,708, 7,915,388, 7,935,343, 8,088,618, 8,691,233, and 9,605,065). No. 8,388,965, and U.S. Patent Application Publication Nos. 2011 / 0008345, 2013 / 0251718, and 2016 / 0207995), and IL-4 receptor (IL-4R) inhibitors (described below). The portions of the publications identifying IL-4 / IL-13 pathway inhibitors cited herein are incorporated herein by reference.

[0047] In some embodiments, the IL-4 / IL-13 pathway inhibitor is an antibody, a small molecule compound, or a combination thereof. The IL-4 / IL-13 pathway inhibitors may be a polypeptide, nucleic acid, or functional fragment or variant thereof. Non-limiting examples of suitable IL-4 / IL-13 pathway inhibitor antibodies include anti-IL-4 antibodies, anti-IL-13 antibodies, and anti-IL-4 / IL-13 bispecific antibodies, anti-IL-4R antibodies, and any antigen-binding fragments of the foregoing antibodies. Other non-limiting examples of suitable IL-4 / IL-13 pathway inhibitors include RNAi molecules, such as anti-IL-4 RNAi molecules and anti-IL-13 RNAi molecules, antisense molecules, such as anti-IL-4 antisense RNA and anti-IL-13 antisense RNA, and dominant negative proteins, such as dominant negative IL-4 proteins, dominant negative IL-13 proteins.

[0048] As used herein, an "IL-4R inhibitor" (also referred to herein as an "IL-4 / IL-13 pathway inhibitor", "IL-4Rα antagonist", "IL-4R blocker", "IL-4Rα blocker", etc.) is any agent that binds to or interacts with IL-4Rα or an IL-4R ligand and inhibits or attenuates the normal biological signaling function of type 1 and / or type 2 IL-4 receptors. Type 1 IL-4 receptors are dimeric receptors that include an IL-4Rα chain and a γc chain. Type 2 IL-4 receptors are dimeric receptors that include an IL-4Rα chain and an IL-13Rα1 chain. Type 1 IL-4 receptors interact with and are stimulated by IL-4, while type 2 IL-4 receptors interact with and are stimulated by both IL-4 and IL-13. Thus, IL-4R inhibitors that may be used in the methods of the present disclosure may function by blocking IL-4-mediated signaling, IL-13-mediated signaling, or both IL-4- and IL-13-mediated signaling. Thus, the IL-4R inhibitors of the present disclosure may prevent the interaction of IL-4 and / or IL-13 with the type 1 or type 2 receptors.

[0049] Non-limiting examples of categories of IL-4R inhibitors include IL-4 muteins (e.g., pitrakinra), small molecule IL-4R inhibitors, anti-IL-4R aptamers, peptide-based IL-4R inhibitors (e.g., "peptibody" molecules), "receptorbodies" (e.g., engineered molecules that contain the ligand-binding domain of an IL-4R component), and antibodies or antigen-binding fragments of antibodies that specifically bind to human IL-4Rα. As used herein, IL-4R inhibitors also include antigen-binding proteins that specifically bind to IL-4 and / or IL-13.

[0050] Other non-limiting examples of suitable IL-4 / IL-13 pathway inhibitors that may be used in the context of the present disclosure include, for example, pitrakinra (AER-001; BAY-16-9996), Aeroderm (AER-003), and antibodies referred to and known in the art as dupilumab, pascolizumab, AMG-317, MILR1444A, CAT-354, QAX576, anrukinzumab (IMA-638), ISIS-369645 (AIR-645), IMA-026, APG-201, CNTO-607, MK-6105, MEDI9314, MEDI2045, tralokinumab, lebrikizumab, romilkimab, and DOM-0910.

[0051] Anti-IL-4Rα antibodies and antigen-binding fragments thereof According to certain exemplary embodiments of the present disclosure, the IL-4 / IL-13 pathway inhibitor is an anti-IL-4Rα antibody or an antigen-binding fragment thereof. The term "antibody" as used throughout this disclosure includes immunoglobulin molecules comprising four polypeptide chains, two heavy (H) chains and two light (L) chains, interconnected by disulfide bonds, as well as multimers thereof (e.g., IgM). In a typical antibody, each heavy chain comprises a heavy chain variable region (referred to herein as HCVR or V H The heavy chain constant region is made up of three domains: H 1. C H 2 and C H Each light chain comprises a light chain variable region (referred to herein as LCVR or VL The light chain constant region comprises one Domain (C L 1) is included. H and V L The region can be further subdivided into regions of hypervariability called complementarity determining regions (CDRs), interspersed with more conserved regions called framework regions (FRs). H and V L is composed of three CDRs and four FRs, arranged in the following order from amino-terminus to carboxy-terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In different embodiments of the present disclosure, the FRs of the antibody (or antigen-binding portion thereof) may be identical to human germline sequences or may be naturally or artificially modified. An amino acid consensus sequence may be defined based on a side-by-side analysis of two or more CDRs.

[0052] The term "antibody" as used throughout this disclosure includes antigen-binding fragments thereof, i.e., antigen-binding fragments of the entire antibody molecule. As used throughout this disclosure, the terms "antigen-binding portion" of an antibody, "antigen-binding fragment" of an antibody, and the like include any naturally occurring, enzymatically derived, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds to an antigen to form a complex. Antigen-binding fragments of antibodies can be obtained from full-length antibody molecules using any suitable standard technique, such as, for example, proteolysis, or recombinant genetic engineering techniques, including the manipulation and expression of DNA encoding antibody variable domains, and optionally constant domains. Such DNA is known and / or readily available, for example, from commercial sources, DNA libraries (including, for example, phage antibody libraries), or can be synthesized. The DNA can be sequenced and manipulated, for example, chemically or using molecular biology techniques, to place one or more variable and / or constant domains in the appropriate configuration, or to introduce codons, create cysteine ​​residues, modify, add, or delete amino acids, and the like.

[0053] Non-limiting examples of antigen-binding fragments include (i) Fab fragments; (ii) F(ab')2 fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single chain Fv (scFv) molecules; (vi) dAb fragments; and (vii) minimal recognition units consisting of amino acid residues mimicking the hypervariable regions of an antibody (e.g., isolated complementarity determining regions (CDRs) such as CDR3 peptides) or constrained FR3-CDR3-FR4 peptides. Domain-specific antibodies, single domain antibodies, domain deleted antibodies, chimeric antibodies, CDR-grafted antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (e.g., monovalent nanobodies, bivalent nanobodies, etc.), small modular immunopharmaceuticals (SMIPs), and other engineered molecules such as shark variable IgNAR domains are also included in the expression "antigen-binding fragment" as used throughout this disclosure.

[0054] An antigen-binding fragment of an antibody will typically contain at least one variable domain. The variable domain may be of any size or amino acid composition, but generally contains at least one CDR adjacent to or in frame with one or more framework sequences. L V related to domain H In an antigen-binding fragment having a domain, H Domain and V L The domains may be arranged relative to each other in any suitable configuration. For example, the variable region may be a dimer, with the V H -V H , V H -V L or V L -V L Alternatively, the antigen-binding fragment of the antibody may comprise a monomeric V H or V L It may include a domain.

[0055] In certain embodiments, an antigen-binding fragment of an antibody may comprise at least one variable domain covalently linked to at least one constant domain. Non-limiting exemplary configurations of variable and constant domains that may be found within an antigen-binding fragment of an antibody of the present disclosure include: (i) a V H -C H 1;(ii)V H -C H 2;(iii)V H -C H 3;(iv)V H -C H 1-C H 2;(v)V H -C H 1-C H 2-C H 3;(vi)V H -C H 2-C H 3;(vii)V H -C L ;(viii)V L -C H 1;(ix)V L -C H 2;( x)V L -C H 3;(xi)V L -C H 1-C H 2;(xii)V L -C H 1-C H 2-C H 3;(xiii)V L -C H 2-C H 3; and (xiv) V L -C LIn any configuration of variable and constant domains, including any of the exemplary configurations listed above, the variable and constant domains may be directly linked to each other or may be linked by a complete or partial hinge or linker region. The hinge region may consist of at least two (e.g., 5, 10, 15, 20, 40, 60 or more) amino acids that provide a flexible or semi-flexible linkage between adjacent variable and / or constant domains within a single polypeptide molecule. Additionally, antigen-binding fragments of antibodies of the present disclosure may be linked to each other (e.g., by disulfide bonds) and / or to one or more monomeric V H or V L The domains may comprise homodimers or heterodimers (or other multimers) of any of the variable and constant domain configurations listed above, non-covalently associated with each other.

[0056] The term "antibody" as used throughout this disclosure also includes multispecific (e.g., bispecific) antibodies. Multispecific antibodies or antigen-binding fragments of antibodies typically contain at least two different variable domains, where each variable domain can specifically bind to a separate antigen or a different epitope on the same antigen. Any multispecific antibody format can be adapted for use in the context of the antibodies or antigen-binding fragments of antibodies of the present disclosure using routine techniques available in the art. For example, the present disclosure includes methods that include the use of bispecific antibodies, where one arm of the immunoglobulin is specific for IL-4Rα or a fragment thereof, and the other arm of the immunoglobulin is specific for a second therapeutic target or is conjugated to a therapeutic drug moiety. Exemplary bispecific formats that may be used in the context of the present disclosure include, but are not limited to, for example, scFv-based or diabody bispecific formats, IgG-scFv fusions, dual variable domain (DVD)-Ig, quadromas, knobs-into-holes, common light chains (such as common light chains with knobs-into-holes), cross-Mab, cross-Fab, (seed)bodies, leucine zippers, duobodies, IgG1 / IgG2, dual acting Fab (DAF)-IgG, and Mab 2 Bispecific formats include (for a review of the aforementioned formats, see, e.g., Klein et al., 2012, mAbs 4(6):653-663, and references cited therein). Bispecific antibodies can also be constructed using peptide / nucleic acid linkages, e.g., using unnatural amino acids with orthogonal chemical reactivity to generate site-specific antibody-oligonucleotide conjugates that self-assemble into multimeric complexes with defined composition, valency, and shape. (See, e.g., Kazane et al., J. Am. Chem. Soc., 2013, 135(1):340-46).

[0057] The antibody used in the method of the present disclosure may be a human antibody. The term "human antibody" as used throughout this disclosure is intended to include antibodies with variable and constant regions derived from human germline immunoglobulin sequences. The human antibody of the present disclosure may still include amino acid residues (e.g., mutations introduced by in vitro random or site-specific mutagenesis or in vivo somatic mutation) that are not encoded by human germline immunoglobulin sequences, for example in the CDRs, particularly CDR3. However, the term "human antibody" as used throughout this disclosure is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, are grafted onto human framework sequences.

[0058] The antibodies used in the methods of the present disclosure may be recombinant human antibodies. As used throughout this disclosure, the term "recombinant human antibody" refers to antibodies expressed using a recombinant expression vector (described further below) transfected into a host cell, recombinant combinatorial antibodies It is intended to include all human antibodies that are prepared, expressed, produced, or isolated by recombinant methods, such as antibodies isolated from human antibody libraries (described further below), antibodies isolated from animals (e.g., mice) transgenic for human immunoglobulin genes (see, e.g., Taylor et al., (1992) Nucl. Acids Res., 20:6287-6295), or antibodies prepared, expressed, produced, or isolated by any other means involving splicing human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences. However, in certain embodiments, such recombinant human antibodies are subjected to in vitro mutagenesis (or, when animals transgenic for human Ig sequences are used, in vivo somatic mutagenesis) to thereby modify the V and V regions of the recombinant antibodies. H and V L The amino acid sequence of the region is human germline V H and V LThese are sequences that are derived from and related to the sequence, but may not naturally occur within the human antibody germline repertoire in vivo.

[0059] According to certain embodiments, the antibody used in the method of the present disclosure specifically binds to IL-4Rα. Terms such as "specifically bind" mean that the antibody or its antigen-binding fragment forms a relatively stable complex with the antigen under physiological conditions. Methods for determining whether an antibody specifically binds to an antigen are well known in the art and include, for example, equilibrium dialysis, surface plasmon resonance, and the like. For example, in some embodiments, an antibody that "specifically binds" to IL-4Rα as used in the context of the present disclosure has a K of less than about 500 nM, less than about 300 nM, less than about 200 nM, less than about 100 nM, less than about 90 nM, less than about 80 nM, less than about 70 nM, less than about 60 nM, less than about 50 nM, less than about 40 nM, less than about 30 nM, less than about 20 nM, less than about 10 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less than about 2 nM, less than about 1 nM, or less than about 0.5 nM as measured by a surface plasmon resonance assay. D The present invention includes antibodies that specifically bind to IL-4Rα or a portion thereof. However, an isolated antibody that specifically binds to human IL-4Rα may have cross-reactivity to other antigens, such as IL-4Rα molecules from other (non-human) species.

[0060] According to certain exemplary embodiments of the present disclosure, the IL-4 / IL-13 pathway inhibitor is an anti-IL-4Rα antibody or antigen-binding fragment thereof, comprising a heavy chain variable region (HCVR), a light chain variable region (LCVR), and / or a complementarity determining region (CDR) comprising any of the amino acid sequences of the anti-IL-4R antibodies described in U.S. Patent No. 7,608,693, which is incorporated herein by reference. In certain exemplary embodiments, the anti-IL-4Rα antibody or antigen-binding fragment thereof that may be used in the context of the methods of the present disclosure comprises a heavy chain complementarity determining region (HCDR) of the heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:1, and a light chain complementarity determining region (LCDR) of the light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:2. According to certain embodiments, the anti-IL-4Rα antibody or antigen-binding fragment thereof comprises three HCDRs (HCDR1, HCDR2 and HCDR3) and three LCDRs (LCDR1, LCDR2 and LCDR3), where HCDR1 comprises the amino acid sequence of SEQ ID NO:3; HCDR2 comprises the amino acid sequence of SEQ ID NO:4; HCDR3 comprises the amino acid sequence of SEQ ID NO:5; LCDR1 comprises the amino acid sequence of SEQ ID NO:6; LCDR2 comprises the amino acid sequence of SEQ ID NO:7; LCDR3 comprises the amino acid sequence of SEQ ID NO:8. In yet other embodiments, the anti-IL-4R antibody or antigen-binding fragment thereof comprises a HCVR comprising SEQ ID NO:1 and a LCVR comprising SEQ ID NO:2. In certain embodiments, the methods of the disclosure comprise the use of an anti-IL-4R antibody, where the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:9. In some embodiments, the anti-IL-4R antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO:10. An exemplary antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:9 and a light chain comprising the amino acid sequence of SEQ ID NO:10 is the fully human anti-IL-4R antibody known as dupilumab (Dupixent™). According to certain exemplary embodiments, the methods of the disclosure include administering dupilumab or a biological equivalent thereof. The term "bioequivalent" with respect to dupilumab refers to an anti-IL-4R antibody or IL-4R binding protein or fragment thereof that is a pharmaceutical equivalent or substitute that does not show a significant difference in absorption rate and / or extent of absorption from dupilumab when administered at the same molar dose under similar experimental conditions, either in a single dose or multiple doses. In the context of the present disclosure, the term refers to an antigen-binding protein that binds to IL-4R that has no clinically meaningful difference from dupilumab in safety, purity, and / or potency.

[0061] According to certain embodiments of the present disclosure, the anti-human IL-4R antibody or antigen-binding fragment thereof comprises an HCVR having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 1. In some embodiments, the anti-human IL-4R antibody or antigen-binding fragment thereof comprises three HCDRs (HCDR1, HCDR2 and HCDR3) comprising the amino acid sequences of SEQ ID NOs: 3, 4 and 5, respectively, and comprises an HCVR having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 1.

[0062] According to certain embodiments of the present disclosure, the anti-human IL-4R antibody or antigen-binding fragment thereof comprises an LCVR having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 2. In some embodiments, the anti-human IL-4R antibody or antigen-binding fragment thereof comprises three LCDRs (LCDR1, LCDR2 and LCDR3) comprising the amino acid sequences of SEQ ID NOs: 6, 7 and 8, respectively, and comprises an LCVR having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 2.

[0063] According to certain embodiments of the present disclosure, the anti-human IL-4R antibody or antigen-binding fragment thereof comprises an HCVR comprising the amino acid sequence of SEQ ID NO: 1 with no more than 5 amino acid substitutions. According to certain embodiments of the present disclosure, the anti-human IL-4R antibody or antigen-binding fragment thereof comprises an LCVR comprising the amino acid sequence of SEQ ID NO: 2 with no more than 2 amino acid substitutions.

[0064] In some embodiments, the anti-human IL-4R antibody or antigen-binding fragment thereof comprises a HCVR having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:1, and a LCVR having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:2. In some embodiments, the anti-human IL-4R antibody or antigen-binding fragment thereof comprises: (a) HCDR1, HCDR2 and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 3, 4 and 5, respectively, and a HCVR having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 1; and (b) LCDR1, LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 6, 7 and 8, respectively, and a LCVR having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 2.

[0065] Sequence identity can be measured by methods known in the art, such as GAP, BESTFIT, and BLAST.

[0066] The present disclosure also includes the use of anti-IL-4R antibodies in methods for treating allergies or eliminating allergen-specific IgE in a subject, wherein the anti-IL-4R antibodies include variants of any of the HCVR, LCVR and / or CDR amino acid sequences disclosed herein having one or more conservative amino acid substitutions. For example, the present disclosure includes the use of anti-IL-4R antibodies having HCVR, LCVR and / or CDR amino acid sequences having, for example, 10 or less, 8 or less, 6 or less, 4 or less, etc., conservative amino acid substitutions compared to any of the HCVR, LCVR and / or CDR amino acid sequences disclosed herein. In some embodiments, the present disclosure includes the use of anti-IL-4R antibodies having HCVR, LCVR and / or CDR amino acid sequences having 1, 2, 3, or 4 conservative amino acid substitutions compared to any of the HCVR, LCVR and / or CDR amino acid sequences disclosed herein.

[0067] Other anti-IL-4Rα antibodies that may be used in the context of the disclosed methods include, for example, the antibody referred to as AMG317 (Corren et al., 2010, Am J Respir Crit Care Med., 181(8):788-796) and known in the art, or MEDI9314, or any of the anti-IL-4Rα antibodies described in U.S. Pat. Nos. 7,186,809, 7,605,237, 7,638,606, 8,092,804, 8,679,487, or 8,877,189. The portions of the publications identifying anti-IL-4Rα antibodies cited herein are incorporated herein by reference.

[0068] The anti-IL-4Rα antibody used in the context of the disclosed method may have pH-dependent binding properties. For example, the anti-IL-4Rα antibody for use in the disclosed method may exhibit reduced binding to IL-4Rα at acidic pH compared to neutral pH. Alternatively, the anti-IL-4Rα antibody of the disclosed disclosure may exhibit enhanced binding to its antigen at acidic pH compared to neutral pH. The term "acidic pH" includes a pH value less than about 6.2, such as about 6.0, 5.95, 5.9, 5.85, 5.8, 5.75, 5.7, 5.65, 5.6, 5.55, 5.5, 5.45, 5.4, 5.35, 5.3, 5.25, 5.2, 5.15, 5.1, 5.05, 5.0 or less. The term "neutral pH" used throughout the present disclosure refers to a pH of about 7.0 to about 7.4. The expression "neutral pH" includes pH values ​​of about 7.0, 7.05, 7.1, 7.15, 7.2, 7.25, 7.3, 7.35 and 7.4.

[0069] In certain instances, "reduced binding to IL-4Rα at acidic pH compared to neutral pH" refers to the K D value and the K of antibodies binding to IL-4Rα at neutral pH D For purposes of this disclosure, an antibody or antigen-binding fragment thereof is expressed in terms of a ratio of the antibody or antigen-binding fragment thereof to an acidic / neutral K value of about 3.0 or greater. D When a ratio is presented, it may be considered to indicate "reduced binding to IL-4Rα at acidic pH compared to neutral pH." In certain exemplary embodiments, the acidic / neutral K D The ratio can be about 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 10.5, 11.0, 11.5, 12.0, 12.5, 13.0, 13.5, 14.0, 14.5, 15.0, 20.0, 25.0, 30.0, 40.0, 50.0, 60.0, 70.0, 100.0, or more.

[0070] Antibodies with pH-dependent binding properties, for example, at acidic pH compared to neutral pH This can be obtained by screening a population of antibodies for reduced (or enhanced) binding to a particular antigen. Furthermore, modification of the antigen-binding domain at the amino acid level can result in an antibody with pH-dependent characteristics. For example, by replacing one or more amino acids of the antigen-binding domain (e.g., in the CDR) with histidine residues, an antibody with reduced antigen binding at acidic pH compared to neutral pH can be obtained. The term "acidic pH" as used throughout this disclosure refers to a pH of 6.0 or less.

[0071] Plasma cell depleting agents The methods disclosed herein include administering a therapeutically effective amount of a plasma cell depleting agent to a subject in need thereof. As used herein, "plasma cell depleting agent" refers to any molecule that can specifically bind to a surface antigen on a plasma cell and kill or remove said plasma cell. In some embodiments, the plasma cell depleting agent can be an antibody, a small molecule compound, a nucleic acid, a polypeptide, or a functional fragment or variant thereof. In the context of the present disclosure, the plasma cell depleting agent is used in combination with an IL-4 / IL-13 pathway inhibitor in the disclosed methods.

[0072] Non-limiting examples of suitable plasma cell depleting agents include BCMA targeting agents (described elsewhere herein), proteasome inhibitors [e.g., bortezomib (Velcade), carfilzomib (Cyprolis), ixazomib (Ninlaro)], histone deacetylase inhibitors [e.g., panobinostat (Faridak)], B-cell activating factor (BAFF; also called BLyS, TALL-1, or CD257) inhibitors (e.g., anti-BAFF antibodies such as belimumab, tabalumab, AMG570, or anti-BAFF receptor antibodies such as ianalumab), and proliferation-inducing ligand (APRIL; also called TNFSF13 or CD256) inhibitors (e.g., anti-APRIL antibodies such as BION-1301 or VIS624).

[0073] BCMA targeting agent According to certain exemplary embodiments, the plasma cell depleting agent used in the methods disclosed herein is a BCMA targeting agent.

[0074] As used herein, the term "BCMA targeting agent" refers to any molecule capable of specifically binding to BCMA expressed on the surface of a cell of interest, and thus targeting said cells for destruction. BCMA is exclusively expressed in B-cell lineage cells, particularly in the interfollicular regions of germinal centers, as well as plasmablasts and differentiated plasma cells. BCMA is selectively induced during plasma cell differentiation and is required for optimal survival of long-lived plasma cells in the bone marrow. Thus, a BCMA targeting agent binds to BCMA expressed on the plasma cell surface and mediates the killing or elimination of cells expressing BCMA (plasma cell elimination). In the context of the present disclosure, in some embodiments, a BCMA targeting agent comprises a binding moiety (antigen-binding moiety or antigen-binding fragment thereof) that binds to plasma cell surface-expressed BCMA and a moiety that promotes killing of said plasma cells. In certain embodiments, the moiety that binds to BCMA expressed on the plasma cell surface is an antibody or antigen-binding fragment thereof that specifically binds to BCMA. Such a BCMA binding moiety is linked (e.g., covalently linked) to a moiety that promotes the killing or destruction of the targeted plasma cells. The moiety that promotes targeted killing of bound plasma cells can be a molecule that directly kills the target cell (e.g., a cytotoxic agent) or can be a protein or fragment thereof that mediates killing of the target cell by an immune cell, e.g., a T cell. In the context of this disclosure, the term "BCMA targeting agent" includes, but is not limited to, an anti-BCMA antibody conjugated to a therapeutic agent such as a cytotoxic drug ("BCMA ADC" or "anti-BCMA ADC"), a chimeric antigen receptor (CAR) that specifically binds to BCMA ("BCMA CAR" or "anti-BCMA CAR"), and an anti-BCMA / anti-CD3 bispecific antibody.

[0075] According to certain embodiments, the BCMA targeting agent used in the context of the disclosed methods is an antibody drug conjugate (ADC) comprising an anti-BCMA antibody and a cytotoxic drug. In some embodiments, the anti-BCMA antibody or antigen-binding fragment thereof and the cytotoxic drug are covalently linked via a linker. In general terms, an ADC is an A-[LP] y wherein A is an antigen-binding molecule, e.g., an anti-BCMA antibody or fragment thereof, L is a linker, P is a payload or therapeutic moiety (e.g., a cytotoxic agent), and y is an integer from 1 to 30. Examples of suitable cytotoxic and chemotherapeutic agents for forming an ADC are known in the art. Non-limiting examples of suitable cytotoxic agents that may be conjugated to an anti-BCMA antibody for use in the disclosed methods are auristatins, such as monomethylauristatin E (MMAE) or monomethylauristatin F (MMAF), tubulysins, such as TUB-OH or TUB-OMOM, tomaymycin derivatives, dolastatin derivatives, or maytansinoids, such as DM1 or DM4. According to certain exemplary embodiments, the present disclosure includes the use of an anti-BCMA ADC in a method of treating allergy, wherein the anti-BCMA ADC comprises any of the amino acid sequences of the HCVR, LCVR and / or CDRs disclosed elsewhere herein.

[0076] The disclosure also includes the use of anti-BCMA ADCs in methods of treating allergies, where the antibodies include variants of any of the HCVR, LCVR and / or CDR amino acid sequences disclosed herein having one or more conservative amino acid substitutions. For example, the disclosure includes the use of antibodies having HCVR, LCVR and / or CDR amino acid sequences with, e.g., 10 or less, 8 or less, 6 or less, 4 or less, etc., conservative amino acid substitutions compared to any of the HCVR, LCVR and / or CDR amino acid sequences disclosed herein. In some embodiments, the disclosure includes the use of antibodies having HCVR, LCVR and / or CDR amino acid sequences with 1, 2, 3, or 4 conservative amino acid substitutions compared to any of the HCVR, LCVR and / or CDR amino acid sequences disclosed herein.

[0077] Other anti-BCMA ADCs that may be used in the context of the methods of the present disclosure include, for example, ADCs referred to and known in the art as belantamab mafodotin, GSK2857916, AMG224, HDP-101, MEDI2228, and TBL-CLN1, or any of the anti-BCMA ADCs described in, for example, patent publications WO2011 / 108008, WO2014 / 089335, WO2017 / 093942, WO2017 / 143069, WO2019 / 025983. The portions of the publications identifying the anti-BCMA ADCs cited herein are incorporated herein by reference.

[0078] According to certain embodiments, the BCMA targeting agent used in the context of the disclosed methods is a chimeric antigen receptor (CAR) that specifically binds to BCMA ("BCMA CAR"). The term "chimeric antigen receptor" (CAR) refers to a molecule that combines a binding domain for a component present on a target cell, e.g., an antibody-based specificity for a desired antigen (e.g., BCMA on plasma cells), with a T cell receptor activation intracellular domain to generate a chimeric protein that exhibits specific anti-target cell immune activity. In general, CARs consist of an extracellular single-chain antibody binding domain (scFv) fused to the intracellular signaling domain of the T cell antigen receptor complex zeta chain, and when expressed in T cells, have the ability to switch antigen recognition based on the specificity of a monoclonal antibody. In certain embodiments, the BCMA CAR or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR), a light chain variable region (LCVR), and a nucleotide sequence comprising the amino acid sequence of any of the antibodies described in U.S. Provisional Patent Application No. 62 / 700,615, filed July 19, 2018, or International Patent Application No. PCT / US2019 / 042452, which are incorporated by reference in their entireties. According to certain exemplary embodiments, the present disclosure includes the use of an anti-BCMA CAR in a method of treating allergy, wherein the anti-BCMA CAR comprises any of the amino acid sequences of HCVR, LCVR and / or CDR disclosed elsewhere herein.

[0079] The present disclosure also includes the use of anti-BCMA CARs in methods of treating allergies, where the CAR comprises a variant of any of the HCVR, LCVR and / or CDR amino acid sequences disclosed herein having one or more conservative amino acid substitutions. For example, the present disclosure includes the use of anti-BCMA CARs having HCVR, LCVR and / or CDR amino acid sequences having, for example, 10 or less, 8 or less, 6 or less, 4 or less, etc., conservative amino acid substitutions compared to any of the HCVR, LCVR and / or CDR amino acid sequences disclosed herein. In some embodiments, the present disclosure includes the use of anti-BCMA CARs having HCVR, LCVR and / or CDR amino acid sequences having 1, 2, 3, or 4 conservative amino acid substitutions compared to any of the HCVR, LCVR and / or CDR amino acid sequences disclosed herein.

[0080] Other anti-BCMA CARs that may be used in the context of the disclosed methods include, for example, the CARs referred to and known in the art as bb2121, LCAR-B38M, and 4C8A, or those described in, for example, patent documents WO2015 / 052538, WO2015 / 052536, WO2016 / 094304, WO2016 / 166630, WO2016 / 151315, WO2016 / 1 30598, WO2017 / 183418, WO2017 / 173256, WO2017211900, WO2017 / 130223, WO2018 / 229492, WO2018 / 085690, WO2018 / 151836, WO2018 / 028647, WO2019 / 006072. The portions of the publications identifying the anti-BCMA CARs cited herein are incorporated herein by reference.

[0081] According to certain exemplary embodiments, the BCMA targeting agent used in the context of the disclosed methods is an anti-BCMA / anti-CD3 bispecific antibody (also referred to herein as an "anti-BCMA x anti-CD3 bispecific antibody"). Anti-BCMA / anti-CD3 bispecific antibodies are useful for specific targeting and T cell-mediated killing of cells expressing BCMA. The terms "antibody", "antigen-binding fragment", "human antibody", "recombinant antibody", and other related terms are defined above. In the context of anti-BCMA / anti-CD3 antibodies and antigen-binding fragments thereof, the present disclosure includes the use of bispecific antibodies, where one arm of the immunoglobulin is specific for BCMA or a fragment thereof, and the other arm of the immunoglobulin is specific for a second therapeutic target (e.g., CD3 on T cells). Exemplary bispecific formats that may be used in the context of the present disclosure include, but are not limited to, for example, scFv-based or diabody bispecific formats, IgG-scFv fusions, dual variable domain (DVD)-Ig, quadromas, knobs-into-holes, common light chains (such as common light chains with knobs-into-holes), cross-Mab, cross-Fab, (seed)bodies, leucine zippers, duobodies, IgG1 / IgG2, dual acting Fab (DAF)-IgG, and Mab 2 Bispecific formats (for reviews of the aforementioned formats, see, e.g., Klein et al., 2012; mAbs 4(6):653-663, and references cited therein). Bispecific antibodies can also be constructed using peptide / nucleic acid linkages, e.g., unnatural amino acids with orthogonal chemical reactivity can be used to generate site-specific antibody-oligonucleotide conjugates that self-assemble into multimeric complexes with defined composition, valency, and shape. (See, e.g., Kazane et al., J. Am. Chem. Soc., 2013, 135(1):340-46).

[0082] Terms such as "specifically bind" mean that the antibody or antigen-binding fragment thereof forms a relatively stable complex with the antigen under physiological conditions. Methods for determining whether an antibody specifically binds to an antigen are well known in the art and include, for example, equilibrium dialysis, surface plasmon resonance, and the like. For example, an antibody that "specifically binds" to BCMA as used in the context of this disclosure has a K of less than about 100 nM, less than about 50 nM, less than about 20 nM, less than about 10 nM, less than about 5 nM, less than about 1 nM, less than about 500 pM, less than about 200 pM, less than about 100 pM, or less than about 50 pM as measured by a surface plasmon resonance assay. D An isolated antibody that specifically binds human BCMA may, however, have cross-reactivity to other antigens, such as BCMA molecules from other (non-human) species.

[0083] According to certain exemplary embodiments, the anti-BCMA / anti-CD3 bispecific antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR), a light chain variable region (LCVR), and / or a complementarity determining region (CDR) comprising the amino acid sequence of any of the antibodies described in U.S. Provisional Patent Application No. 62 / 793,645, filed January 17, 2019, or International Patent Application No. PCT / US2019 / 042447, which are incorporated by reference in their entireties. In certain exemplary embodiments, the anti-BCMA / anti-CD3 bispecific antibody or antigen-binding fragment thereof that may be used in the context of the present disclosure comprises (a) a first antigen-binding domain that specifically binds BCMA; and (b) a second antigen-binding domain that specifically binds CD3. In one embodiment, the first antigen-binding domain comprises a heavy chain complementarity determining region (HCDR) of the heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 12 and a light chain complementarity determining region (LCDR) of the light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 20. According to a particular embodiment, the first antigen-binding domain comprises three HCDRs (HCDR1, HCDR2 and HCDR3) and three LCDRs (LCDR1, LCDR2 and LCDR3), wherein HCDR1 comprises the amino acid sequence of SEQ ID NO: 14; HCDR2 comprises the amino acid sequence of SEQ ID NO: 16; HCDR3 comprises the amino acid sequence of SEQ ID NO: 18; LCDR1 comprises the amino acid sequence of SEQ ID NO: 22; LCDR2 comprises the amino acid sequence of SEQ ID NO: 24; and LCDR3 comprises the amino acid sequence of SEQ ID NO: 26. In one embodiment, the second antigen-binding domain comprises a heavy chain complementarity determining region (HCDR) of a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 28 or SEQ ID NO: 36 and a light chain complementarity determining region (LCDR) of a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 20.In one embodiment, the second antigen-binding domain comprises three HCDRs (HCDR1, HCDR2 and HCDR3) and three LCDRs (LCDR1, LCDR2 and LCDR3), wherein HCDR1 comprises the amino acid sequence of SEQ ID NO: 30 or 38; HCDR2 comprises the amino acid sequence of SEQ ID NO: 32 or 40; HCDR3 comprises the amino acid sequence of SEQ ID NO: 34 or 42; LCDR1 comprises the amino acid sequence of SEQ ID NO: 22; LCDR2 comprises the amino acid sequence of SEQ ID NO: 24; and LCDR3 comprises the amino acid sequence of SEQ ID NO: 26.

[0084] In one embodiment, the anti-BCMA / anti-CD3 bispecific antibody or antigen-binding fragment thereof comprises: (a) a first antigen-binding domain comprising HCDR1, HCDR2 and HCDR3 domains comprising the amino acid sequences of SEQ ID NOs: 14, 16 and 18, respectively, and LCDR1, LCDR2 and LCDR3 domains comprising the amino acid sequences of SEQ ID NOs: 22, 24 and 26, respectively; and (b) a second antigen-binding domain comprising HCDR1, HCDR2 and HCDR3 domains comprising the amino acid sequences of SEQ ID NOs: 30, 32 and 34, respectively, and LCDR1, LCDR2 and LCDR3 domains comprising the amino acid sequences of SEQ ID NOs: 22, 24 and 26, respectively. In one embodiment, the anti-BCMA / anti-CD3 bispecific antibody or antigen-binding fragment thereof comprises: (a) a first antigen-binding domain comprising a HCVR comprising the amino acid sequence of SEQ ID NO: 12 and a LCVR comprising the amino acid sequence of SEQ ID NO: 20; and (b) a HCVR comprising the amino acid sequence of SEQ ID NO: 28. and a second antigen-binding domain comprising an LCVR comprising the amino acid sequence of SEQ ID NO: 20.

[0085] In one embodiment, the anti-BCMA / anti-CD3 bispecific antibody or antigen-binding fragment thereof comprises: (a) a first antigen-binding domain comprising HCDR1, HCDR2 and HCDR3 domains comprising the amino acid sequences of SEQ ID NOs: 14, 16 and 18, respectively, and LCDR1, LCDR2 and LCDR3 domains comprising the amino acid sequences of SEQ ID NOs: 22, 24 and 26, respectively; and (b) a second antigen-binding domain comprising HCDR1, HCDR2 and HCDR3 domains comprising the amino acid sequences of SEQ ID NOs: 38, 40 and 42, respectively, and LCDR1, LCDR2 and LCDR3 domains comprising the amino acid sequences of SEQ ID NOs: 22, 24 and 26, respectively. In one embodiment, the anti-BCMA / anti-CD3 bispecific antibody or antigen-binding fragment thereof comprises: (a) a first antigen-binding domain comprising a HCVR comprising the amino acid sequence of SEQ ID NO: 12 and a LCVR comprising the amino acid sequence of SEQ ID NO: 20; and (b) a second antigen-binding domain comprising a HCVR comprising the amino acid sequence of SEQ ID NO: 36 and a LCVR comprising the amino acid sequence of SEQ ID NO: 20.

[0086] Exemplary anti-BCMA / anti-CD3 bispecific antibodies include the fully human bispecific antibodies known as REGN5458 and REGN5459. According to certain exemplary embodiments, the methods of the disclosure include the use of REGN5458 or REGN5459, or their biological equivalents. As used herein, the term "bioequivalent" with respect to an anti-BCMA / anti-CD3 antibody refers to an antibody or BCMA / CD3 binding protein or fragment thereof that is a pharmaceutical equivalent or pharmaceutical substitute that has a rate and / or extent of absorption that is not significantly different from a reference antibody (e.g., REGN5458 or REGN5459) when administered under similar experimental conditions, at the same molar dose, either in a single dose or multiple doses; the term "bioequivalent" also includes antigen binding proteins that bind BCMA / CD3 and have no clinically meaningful differences from a reference antibody (e.g., REGN5458 or REGN5459) in terms of safety, purity and / or potency.

[0087] In some embodiments, the anti-BCMA / anti-CD3 bispecific antibody or antigen-binding fragment thereof comprises: (a) a HCVR having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 12, and a HCVR having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 20. and (b) a HCVR having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of SEQ ID NO:28, and a second antigen-binding domain comprising a LCVR having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of SEQ ID NO:20. In some embodiments, the anti-BCMA / anti-CD3 bispecific antibody or antigen-binding fragment thereof comprises: (a) three HCDRs (HCDR1, HCDR2 and HCDR3) comprising the amino acid sequences of SEQ ID NOs: 14, 16 and 18, respectively, and three LCDRs (LCDR1, LCDR2 and LCDR3) comprising the amino acid sequences of SEQ ID NOs: 22, 24 and 26, respectively, that have at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 12. and (b) a first antigen-binding domain comprising three HCDRs (HCDR1, HCDR2 and HCDR3) comprising the amino acid sequences of SEQ ID NOs: 30, 32 and 34, respectively, and a HCVR having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of SEQ ID NO: 28; a second antigen-binding domain comprising three LCDRs (LCDR1, LCDR2 and LCDR3) comprising the amino acid sequences of SEQ ID NOs: 22, 24 and 26, respectively, and an LCVR having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 20.

[0088] In some embodiments, the anti-BCMA / anti-CD3 bispecific antibody or antigen-binding fragment thereof comprises: (a) a HCVR having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 12, and a HCVR having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 20. and (b) a HCVR having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of SEQ ID NO: 36, and a second antigen-binding domain comprising a LCVR having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of SEQ ID NO: 20.In some embodiments, the anti-BCMA / anti-CD3 bispecific antibody or antigen-binding fragment thereof comprises: (a) three HCDRs (HCDR1, HCDR2 and HCDR3) comprising the amino acid sequences of SEQ ID NOs: 14, 16 and 18, respectively, and a HCVR having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 12, and three LCDRs (LCDR1, LCDR2 and LCDR3) comprising the amino acid sequences of SEQ ID NOs: 22, 24 and 26, respectively, and a HCVR having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 20. and (b) a second antigen-binding domain comprising three HCDRs (HCDR1, HCDR2 and HCDR3) comprising the amino acid sequences of SEQ ID NOs: 38, 40 and 42, respectively, and a HCVR having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 36, and three LCDRs (LCDR1, LCDR2 and LCDR3) comprising the amino acid sequences of SEQ ID NOs: 22, 24 and 26, respectively, and a LCVR having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 20.

[0089] The disclosure also includes the use of anti-BCMA / anti-CD3 antibodies in methods of treating allergies, where the antibodies include variants of any of the HCVR, LCVR and / or CDR amino acid sequences disclosed herein having one or more conservative amino acid substitutions. For example, the disclosure includes the use of anti-BCMA / anti-CD3 antibodies having HCVR, LCVR and / or CDR amino acid sequences with, for example, 10 or less, 8 or less, 6 or less, 4 or less, etc., conservative amino acid substitutions compared to any of the HCVR, LCVR and / or CDR amino acid sequences disclosed herein. In some embodiments, the disclosure includes the use of anti-BCMA / anti-CD3 antibodies having HCVR, LCVR and / or CDR amino acid sequences with 1, 2, 3, or 4 conservative amino acid substitutions compared to any of the HCVR, LCVR and / or CDR amino acid sequences disclosed herein.

[0090] Other anti-BCMA / anti-CD3 antibodies that may be used in the context of the disclosed methods include, for example, antibodies designated and known in the art as AMG420, AMG701, CC-93269, EM801, JNJ-64007957, and TNB384B, or those described in, for example, patent documents WO2013 / 072415, WO2014 / 140248, WO2014 / 122144, WO2016 / 166629, WO2016 / 079177, WO2016 / 020332, WO2017031104, WO2017 / 223111, WO2017 / 13 4134, WO2018 / 083204, WO2018 / 201051. The portions of the publications identifying the anti-BCMA / anti-CD3 antibodies cited herein are hereby incorporated by reference.

[0091] IgE depletion combined with allergen immunotherapy The present disclosure also provides methods for enhancing the efficacy and / or tolerability of an immunotherapy regimen (e.g., an allergen-specific immunotherapy regimen) in an allergic subject. In some embodiments, the methods include administering an IL-4 / IL-13 pathway inhibitor (such as an anti-IL-4R antibody) and a plasma cell depleting agent (such as an anti-BCMA / anti-CD3 antibody) to the allergic subject prior to or concurrently with the immunotherapy regimen.

[0092] In some embodiments, the subject to be treated has a food allergy. For example, in some embodiments, the subject has an allergy to milk, dairy products, eggs, celery, sesame, wheat, meat, fruit, soy, fish, shellfish, sugar, peanuts, legumes, nuts, or a combination thereof. In some embodiments, the subject has a peanut allergy. In some embodiments, the subject to be treated has a non-food allergy (e.g., an allergy to an environmental allergen). For example, in some embodiments, the subject has an allergy to a non-food allergen selected from the group consisting of dust, dust mites, pollen, insect venom, mold, animal fur, animal dander, wool, latex, metal, household cleaners, detergents, medicines, cosmetics, perfumes, drugs such as penicillin, sulfonamides, salicylates, therapeutic monoclonal antibodies (e.g., cetuximab), ragweed, grass, and birch. In some embodiments, the subject to be treated has a severe allergy (e.g., a severe food allergy or a severe non-food allergy).

[0093] As used herein, "allergen-specific immunotherapy" refers to the repeated administration of an allergen (e.g., an allergen disclosed herein) to a subject over time as a means to treat or prevent allergies and allergic reactions, or to reduce or eliminate allergic reactions. In some embodiments, the allergen-specific immunotherapy regimen comprises oral immunotherapy. In some embodiments, the allergen-specific immunotherapy regimen comprises subcutaneous immunotherapy. In some embodiments, the allergen-specific immunotherapy regimen comprises sublingual immunotherapy. In general, the immunotherapy regimen may be a "conventional" immunotherapy regimen or an "accelerated" immunotherapy regimen. Typically, in a conventional immunotherapy regimen, increasing doses (also called "escalation") of allergen are administered to the patient at weekly intervals over a period of weeks to months (e.g., over 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months or more) under closely monitored medical supervision, followed by a maintenance regimen that typically includes administering one or more doses of allergen at the highest dose administered during the escalation regimen. In an accelerated immunotherapy regimen, the escalation schedule is accelerated compared to conventional immunotherapy. Examples of accelerated immunotherapy include "rush" immunotherapy and "cluster" immunotherapy. In rush immunotherapy, typically increasing doses of allergen are administered daily for several consecutive days (e.g., over 2, 3, 4, 5, 6 days, or 1 week) until the maximum tolerated dose is reached. In cluster immunotherapy, typically several (e.g., 2-3) increasing doses of an allergen are administered on a daily basis over several non-consecutive days until the maximum tolerated dose is reached, usually within 4-8 weeks.

[0094] In some embodiments, the IL-4 / IL-13 pathway inhibitor and the plasma cell depleting agent are administered prior to or concurrently with an allergen-specific immunotherapy regimen as disclosed herein (e.g., oral, sublingual, or subcutaneous immunotherapy, which may be conventional immunotherapy or accelerated immunotherapy). In some embodiments, the plasma cell depleting agent (e.g., 1, 2, 3, 4, 5 or more doses) is administered prior to the initiation of the immunotherapy regimen. In some embodiments, the IL-4 / IL-13 pathway inhibitor (e.g., 1, 2, 3, 4, 5 or more doses) is administered prior to the initiation of the immunotherapy regimen. In some embodiments, at least one dose of each of the plasma cell depleting agent and the IL-4 / IL-13 pathway inhibitor is administered prior to the initiation of the immunotherapy regimen. In some embodiments, the IL-4 / IL-13 pathway inhibitor is administered simultaneously with the immunotherapy regimen. In some embodiments, the plasma cell depleting agent is administered simultaneously with the immunotherapy regimen.

[0095] Pharmaceutical Compositions and Administration The disclosed method includes administering an IL-4 / IL-13 pathway inhibitor in combination with a plasma cell depleting agent to a subject in need thereof, where the inhibitor is contained in a separate pharmaceutical composition or a combined (single) pharmaceutical composition. The pharmaceutical compositions of the present disclosure may be formulated with pharma- ceutically acceptable carriers, excipients, and other agents that provide suitable transfer, delivery, tolerability, and the like. A large number of suitable formulations can be found in formularies known to any medicinal chemist: Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA. These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic)-containing vesicles (such as Lipofectin™), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. Powell et al., 1998, J. See also Pharm Sci Technol, 52:238-311.

[0096] In some embodiments, the disclosed pharmaceutical compositions comprise a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor (such as an anti-IL-4R antibody) and / or a therapeutically effective amount of a plasma cell depleting agent (such as an anti-BCMA / anti-CD3 antibody) and a pharma- ceutical acceptable carrier. In certain embodiments, the disclosed pharmaceutical compositions are formulated for administration by injection, such as intravenous injection.

[0097] A variety of delivery systems are known and may be used to administer the pharmaceutical compositions of the present disclosure, such as, for example, encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing mutant viruses, receptor-mediated endocytosis, etc. (see, for example, Wu et al., 1987, J. Biol. Chem. 262:4429-4432). Methods of administration include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compositions may be administered by any convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.), and may be administered together with other biologically active agents. In some embodiments, the IL-4 / IL-13 pathway inhibitor and / or plasma cell depleting agent is administered intravenously. In some embodiments, the IL-4 / IL-13 pathway inhibitor and / or plasma cell depleting agent is administered subcutaneously.

[0098] In some embodiments, the pharmaceutical composition of the present disclosure is contained in a container.Accordingly, in another aspect, a container is provided that comprises the pharmaceutical composition disclosed herein.For example, in some embodiments, the pharmaceutical composition is contained in a container selected from the group consisting of a glass vial, a syringe, a pen delivery device, and an autoinjector.

[0099] In some embodiments, the pharmaceutical compositions of the present disclosure are delivered subcutaneously or intravenously using a standard needle and syringe. In some embodiments, the syringe is a pre-filled syringe. Additionally, for subcutaneous delivery, pen delivery devices or autoinjectors have application in easily delivering the pharmaceutical compositions of the present disclosure. Pen delivery devices can be reusable or disposable. Typically, reusable pen delivery devices are used. The delivery device utilizes a replaceable cartridge containing the pharmaceutical composition. After all of the pharmaceutical composition in the cartridge has been administered and the cartridge is emptied, the empty cartridge can be easily discarded and replaced with a new cartridge containing the pharmaceutical composition. The pen delivery device can then be reused. In a disposable pen delivery device, there is no replaceable cartridge. Rather, a disposable pen delivery device is pre-filled with the pharmaceutical composition held in a reservoir within the device. Once the reservoir is emptied of the pharmaceutical composition, the entire device is discarded.

[0100] Examples of suitable pen and autoinjector delivery devices include, but are not limited to, AutoPen™ (Owen Mumford, Inc., Woodstock, UK), Disetronic™ Pen (Disetronic Medical Systems, Burgdorf, Switzerland), Humalog MIX 75 / 25™ Pen, Humalog™ Pen, Humulin 70 / 30™ Pen (Eli Lilly and Co., Indianapolis, IN), Novopen™ I, II and III (Novo Nordisk, Copenhagen, Denmark), Novopen Jr.™ (Novo Nordisk, Copenhagen, Denmark), BD™ Pen (Becton Dickinson, Franklin Lakes, NJ), OptiPen™, OptiPen Pro™, OptiPen Starlet™, and OptiClick™ (sanofi-aventis, Frankfurt, Germany). Examples of disposable pen delivery devices having utility for subcutaneous delivery of the pharmaceutical compositions of the present disclosure include, but are not limited to, the Solostar™ pen (sanofi-aventis), FlexPen™ (Novo Nordisk), and QuikPen™ (Eli Lilly), the SureClick™ autoinjector (Amgen, Thousand Oaks, Calif.), Penlet™ (Haselmeier, Stuttgart, Germany), EpiPen (Dey, LP), and the Humira™ pen (Abbott Labs, Abbott Park, Ill.).

[0101] In certain circumstances, one or both pharmaceutical compositions may be delivered in a controlled release system. In one embodiment, a pump may be used. In another embodiment, a polymeric material may be used. See Medical Applications of Controlled Release, Langer and Wise (eds.), 1974, CRC Pres., Boca Raton, Fla. In yet another embodiment, the controlled release system may be placed close to the target of the composition, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, 1984, MEDICAL APPLICATIONS OF CONTROLLED RELEASE, vol. 2, pp. 115-138). Other controlled release systems are discussed in Langer, 1990, Science 249:1527-1533.

[0102] Suitable injectable preparations may include dosage forms for intravenous, subcutaneous, intradermal and intramuscular injections, drip infusions, and the like. These injectable preparations may be prepared by known methods. For example, injectable preparations may be prepared, for example, by dissolving, suspending or emulsifying the above-mentioned antibody or its salt in a sterile aqueous or oily medium conventionally used for injections. Aqueous media for injection include, for example, saline, isotonic solutions containing glucose and other adjuvants, and the like, which may be used in combination with suitable solubilizing agents such as alcohol (e.g., ethanol), polyalcohols (e.g., propylene glycol, polyethylene glycol), nonionic surfactants [e.g., polysorbate 80, HCO-50 (polyoxyethylene (50 mol) adduct of hydrogenated castor oil)], and the like. As oily media, for example, sesame oil, soybean oil, and the like may be used in combination with solubilizing agents such as benzyl benzoate, benzyl alcohol, and the like. Injectable preparations prepared in this manner may be used in combination with suitable solubilizing agents such as benzyl benzoate, benzyl alcohol, and the like. The propellant is preferably packed into a suitable ampoule.

[0103] In some embodiments, the pharmaceutical compositions for oral or parenteral use are prepared into dosage forms of unit doses suitable for the dosage of the active ingredient.Such dosage forms in unit doses include, for example, tablets, pills, capsules, injections (ampoules), cartridges, suppositories, etc.

[0104] Injectable formulations of pharmaceutical compositions can be prepared by known methods. For example, injectable formulations can be prepared by dissolving, suspending or emulsifying the inhibitor (e.g., anti-IL-4R antibody) or its salt in a sterile aqueous or oily medium that is conventionally used for injection. Aqueous media for injection include, for example, saline, isotonic solutions containing glucose and other adjuvants, which can be used in combination with suitable solubilizers such as alcohol (e.g., ethanol), polyalcohol (e.g., propylene glycol, polyethylene glycol), nonionic surfactants [e.g., polysorbate 80, HCO-50 (polyoxyethylene (50 mol) adduct of hydrogenated castor oil)], etc. As oily media, for example, sesame oil, soybean oil, etc. can be used in combination with solubilizers such as benzyl benzoate, benzyl alcohol, etc. The injectable formulations thus prepared are preferably filled into suitable injection ampoules. In some embodiments, the injectable formulation may contain a concentration of an inhibitor (eg, an anti-IL-4R antibody) and one or more pharma- ceutically acceptable solvents (eg, distilled water, saline, etc.).

[0105] Exemplary pharmaceutical compositions comprising anti-IL-4R antibodies that may be used in the context of the present disclosure are disclosed, for example, in U.S. Pat. No. 8,945,559, the portions of which that identify pharmaceutical compositions comprising anti-IL-4R antibodies are incorporated herein by reference.

[0106] kit In certain embodiments, the disclosure provides pharmaceutical combinations and kits comprising an IL-4 / IL-13 pathway inhibitor disclosed herein and a plasma cell depleting agent disclosed herein. In some embodiments, the combination or kit comprises an anti-IL-4R antibody disclosed herein (e.g., an anti-IL-4R antibody or antigen-binding fragment thereof comprising HCDR1, HCDR2 and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 3, 4 and 5, respectively, and LCDR1, LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 6, 7 and 8, respectively) and a plasma cell depleting agent disclosed herein (e.g., an anti-BCMA / anti-CD3 bispecific antibody comprising a first antigen-binding domain that specifically binds BCMA; and a second antigen-binding domain that specifically binds CD3). wherein the first antigen-binding domain comprises HCDR1, HCDR2 and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 14, 16 and 18, respectively, and LCDR1, LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 22, 24 and 26, respectively, and the second antigen-binding domain comprises HCDR1 comprising the amino acid sequence of SEQ ID NO: 30 or 38, HCDR2 comprising the amino acid sequence of SEQ ID NO: 32 or 40, HCDR3 comprising the amino acid sequence of SEQ ID NO: 34 or 42, and LCDR1, LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 22, 24 and 26, respectively.

[0107] In some embodiments, a combination or kit comprising an IL-4 / IL-13 pathway inhibitor and a plasma cell depleting agent is for use in the methods disclosed herein. In some embodiments, the combination or kit is for use to treat an allergy or allergic disorder, or to reduce or eliminate allergen-specific serum IgE in a subject. In some embodiments, the combination or kit further comprises one or more additional therapeutic agents disclosed herein.

[0108] In some embodiments, the combination or kit comprising an IL-4 / IL-13 pathway inhibitor and a plasma cell depleting agent is for use in increasing the efficacy and / or tolerability of an immunotherapeutic regimen in a subject with an allergy. Thus, in some embodiments, the combination or kit further comprises one or more reagents for an immunotherapeutic regimen.

[0109] In some embodiments, the kits for use disclosed herein further comprise instructions for use. In some embodiments, the kits for use disclosed herein comprise one or more containers comprising an IL-4 / IL-13 pathway inhibitor and a plasma cell depleting agent. In some embodiments, the kit comprises a first container comprising an IL-4 / IL-13 pathway inhibitor and a second container comprising a plasma cell depleting agent.

[0110] Dosing regimen In some embodiments, the disclosed methods include sequentially administering to a subject in need thereof a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor in combination with a therapeutically effective amount of a plasma cell depleting agent, where each therapeutic agent is administered to the subject in one or more doses, e.g., as part of a particular therapeutic dosing regimen. In certain embodiments, the disclosed methods include administering the inhibitors for additive or synergistic activity to treat an allergic disease or disorder, a mast cell activation disorder, or mastocytosis.

[0111] As used herein, "sequential administration" means that each dose of the inhibitor is administered to the subject at different times, e.g., on different days separated by a predetermined interval (e.g., hours, days, weeks, or months). In some embodiments, the disclosed methods comprise sequentially administering to the subject a single initial dose of an IL-4 / IL-13 pathway inhibitor, followed by one or more subsequent doses of the IL-4 / IL-13 pathway inhibitor. In certain embodiments, the methods further comprise sequentially administering to the subject a single initial dose of a plasma cell depleting agent, followed by one or more subsequent doses of the plasma cell depleting agent.

[0112] In some embodiments, the therapeutic dosing regimen comprises administering one or more doses of an IL-4 / IL-13 pathway inhibitor in combination with one or more doses of a plasma cell depleting agent. In certain embodiments, one or more doses of an IL-4 / IL-13 pathway inhibitor and / or one or more doses of a plasma cell depleting agent are administered to a subject about once a day, once every two days, once every three days, once every four days, once every five days, once every six days, once a week, once every two weeks, once every three weeks, once every four weeks, once a month, once every two months, once every three months, once every four months, or less frequently.

[0113] As used herein, the term "in combination" means that the IL-4 / IL-13 pathway inhibitor is administered before, after, or simultaneously with the plasma cell depleting agent. The term "in combination" also includes sequential or simultaneous administration of the IL-4 / IL-13 pathway inhibitor and the plasma cell depleting agent.

[0114] For example, if the IL-4 / IL-13 pathway inhibitor is administered "before" the plasma cell depleting agent, the IL-4 / IL-13 pathway inhibitor can be administered 150 hours or more, about 150 hours, about 100 hours, about 72 hours, about 60 hours, about 48 hours, about 36 hours, about 24 hours, about 12 hours, about 10 hours, about 8 hours, about 6 hours, about 4 hours, about 2 hours, about 1 hour, about 30 minutes, or about 15 minutes before administration of the plasma cell depleting agent. If the IL-4 / IL-13 pathway inhibitor is administered "after" the plasma cell depleting agent, the IL-4 / IL-13 pathway inhibitor can be administered about 15 minutes, about 30 minutes, about 1 hour, about 2 hours, about 4 hours, about 6 hours, about 8 hours, about 10 hours, about 12 hours, about 24 hours after administration of the plasma cell depleting agent. The IL-4 / IL-13 pathway inhibitor may be administered about 36 hours, about 48 hours, about 60 hours, about 72 hours, or more than 72 hours later. Administration of an IL-4 / IL-13 pathway inhibitor "concurrently" with a plasma cell depleting agent means that the IL-4 / IL-13 pathway inhibitor is administered to the subject in a separate dosage form within 10 minutes (before, after, or simultaneously) of administration of the plasma cell depleting agent, or is administered to the subject as a single combined dosage form including both the IL-4 / IL-13 pathway inhibitor and the plasma cell depleting agent.

[0115] As used herein, an "initial dose" is a dose administered at the beginning of a treatment regimen (also referred to as a "baseline dose"). One or more subsequent doses administered after the initial dose may all contain the same amount of IL-4 / IL-13 pathway inhibitor or plasma cell depleting agent. However, in certain embodiments, the amounts contained in the initial dose and the subsequent doses vary from one another (e.g., adjusted upwards or downwards as appropriate) during the course of treatment. In certain embodiments, one or more (e.g., 1, 2, 3, 4, or 5) doses are administered as "loading doses" at the beginning of a treatment regimen, followed by subsequent doses (e.g., "maintenance doses") administered less frequently. For example, an IL-4 / IL-13 pathway inhibitor or plasma cell depleting agent may be administered to a patient with an allergic disease at a loading dose of about 1 mg to about 20 mg per kg of the patient's body weight, followed by one or more maintenance doses of about 0.1 mg to about 10 mg per kg of the patient's body weight.

[0116] In one exemplary embodiment of the disclosure, each subsequent dose is administered ½ to 14 weeks or more (e.g., ½, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5 weeks or more) after the immediately preceding dose. As used herein, the phrase "immediately preceding dose" refers to the dose of each inhibitor administered to a subject prior to administration of the next dose in a series of multiple administrations, without any intervening doses.

[0117] Dosage In certain embodiments, at least one dose of the IL-4 / IL-13 pathway inhibitor comprises about 0.1-50 mg / kg, e.g., about 0.1-10 mg / kg of the subject's body weight. For example, at least one dose can comprise about 0.1, 1, 0.3, 3, 4, 5, 6, 7, 8, 9, or 10 mg / kg of the subject's body weight. In certain embodiments, at least one dose of an IL-4 / IL-13 pathway inhibitor comprises about 0.05-600 mg, e.g., about 5-600 mg, about 10-300 mg, about 50-600 mg, or about 50-300 mg of an IL-4 / IL-13 pathway inhibitor, such as about 5, 10, 15, 20, 25, 40, 45, 50, 60, 70, 80, 90, 100, 200, 300, 400 mg, 500 mg, 600 mg or more of an IL-4 / IL-13 pathway inhibitor. In one embodiment, the IL-4 / IL-13 pathway inhibitor is REGN668 (dupilumab).

[0118] In certain embodiments, at least one dose of the plasma cell depleting agent comprises about 0.1-20 mg per kg of the subject's body weight, such as about 0.1, 1, 0.3, 3, 4, 5, 6, 7, 8, 9, or 10 mg per kg of the subject's body weight. In certain embodiments, at least one dose of the plasma cell depleting agent comprises about 0.05-500 mg of plasma cell depleting agent, such as about 5, 10, 15, 20, 25, 40, 45, 50, 60, 70, 80, 90, 100 mg or more of plasma cell depleting agent. In one embodiment, the plasma cell depleting agent is an anti-BCMA / anti-CD3 bispecific antibody (such as REGN5459). In one embodiment, the plasma cell depleting agent is a proteasome inhibitor, such as bortezomib.

[0119] The amount of IL-4 / IL-13 pathway inhibitor and plasma cell depleting agent administered to a subject according to the methods disclosed herein is a therapeutically effective amount. The term "efficacious amount" means the amount of each therapeutic agent that results in one or more of the following: (a) a reduction in the severity or duration of a symptom or sign of allergy, e.g., anaphylaxis; (b) a reduction in the level of serum allergen-specific IgE; (c) elimination of serum IgE in a subject; (d) a reduction in allergen sensitization; (e) a reduction in susceptibility to allergic reactions, and / or; (f) a reduction in the use or need for conventional anti-allergy therapy (e.g., a reduction or elimination of the use of corticosteroids) compared to untreated subjects or subjects treated with either therapeutic agent as monotherapy.

[0120] For IL-4 / IL-13 pathway inhibitors (e.g., anti-IL-4R antibodies), a therapeutically effective amount may be from about 0.05 mg to about 600 mg, e.g., about 0.05 mg, about 0.1 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about The amount of the IL-4 / IL-13 pathway inhibitor may be about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, or about 600 mg. In certain embodiments, 10 mg, 25 mg, 50 mg, 75 mg, 150 mg, or 300 mg of an IL-4 / IL-13 pathway inhibitor is administered to the subject.

[0121] In the case of a plasma cell depleting agent (e.g., an anti-BCMA / anti-CD3 bispecific antibody), the therapeutically effective amount can be from about 0.05 mg to about 500 mg, from about 1 mg to about 500 mg, from about 10 mg to about 450 mg, from about 50 mg to about 400 mg, from about 75 mg to about 350 mg, or from about 100 mg to about 300 mg of antibody. For example, in various embodiments, the amount of plasma cell depleting agent is about 0.05 mg, about 0.1 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 240 mg, about 260 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 0 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, or about 500 mg of plasma cell depleting agent.

[0122] In certain embodiments, the individual doses of IL-4 / IL-13 pathway inhibitors (e.g., anti-IL-4R antibodies) and / or plasma cell depleting agents (e.g., anti-BCMA / anti-CD3 antibodies) administered to a subject may be less than a therapeutically effective amount, i.e., sub-therapeutic doses. For example, if a therapeutically effective amount of an inhibitor comprises 3 mg / kg, a sub-therapeutic dose comprises an amount less than 3 mg / kg, e.g., 2 mg / kg, 1.5 mg / kg, 1 mg / kg, 0.5 mg / kg, or 0.3 mg / kg. As defined herein, a "sub-therapeutic dose" refers to an amount of an inhibitor that does not provide a therapeutic effect by itself. However, in certain embodiments, multiple sub-therapeutic doses of an inhibitor may be administered to collectively achieve a therapeutic effect in a subject.

[0123] Working Example The disclosed technology will now be described with the following examples. The use of these and other examples herein is merely illustrative and in no way limits the scope and meaning of the disclosed or exemplified forms. Similarly, the disclosure is not limited to the specific preferred embodiments described herein. Indeed, modifications and variations of the disclosure will become apparent to those skilled in the art upon reading the specification and may be made without departing from its spirit and scope. Thus, the disclosure should be limited only by the terms of the claims, along with the full range of equivalents to which the claims are entitled. Also, while efforts have been made to ensure accuracy with respect to the numerical values ​​used (e.g., amounts, temperature, etc.), some experimental error and deviation should be accounted for. Unless otherwise specified, parts are parts by weight, molecular weight is average molecular weight, temperature is degrees Celsius, and pressure is atmospheric or near atmospheric pressure. EXAMPLES

[0124] Effect of anti-IL-4R antibody in combination with anti-BCMA / anti-CD3 bispecific antibody This example relates to studies demonstrating the enhanced efficacy of an IL-4 / IL-13 pathway inhibitor in combination with a plasma cell depleting agent in blocking IgE production in a mouse model of chronic allergen-induced pulmonary inflammation.

[0125] The IL-4 / IL-13 pathway inhibitor used in this example was a mouse anti-IL-4R antibody identified as REGN1103, which is a mouse surrogate antibody of a human monoclonal antibody against human IL-4R identified as REGN668 (also known as dupilumab). REGN1103 contains the HCVR / LCVR amino acid sequence pair of SEQ ID NO: 43 / 44 and has affinity for mouse IL-4R in a similar range to that of dupilumab for human IL-4R. Furthermore, REGN1103 inhibits the proliferation of IL-4 and IL-13 dependent cell lines with IC50 of 1.9 nM and 11 pM, respectively.

[0126] The plasma cell depleting agent used in this example is the anti-BCMA / anti-CD3 bispecific antibody REGN5459, which comprises an anti-BCMA binding domain comprising the HCVR of SEQ ID NO: 12 and the LCVR of SEQ ID NO: 20, and an anti-CD3 binding domain comprising the HCVR of SEQ ID NO: 36 and the LCVR of SEQ ID NO: 20.

[0127] material and method To determine the effect of anti-IL-4Rα and anti-BCMA × anti-CD3 combinations on IgE production in a relevant in vivo model, a chronic Dermatophagoides dust mite (HDM)-induced pulmonary inflammation study was performed in mice homozygous for human BCMA and human CD3 instead of mouse BCMA and CD3. Chronic pulmonary inflammation and sustained IgE production were induced by exposing mice to 25 μg HDM (Greer, Cat. No. XBP70D3A25) diluted in 20 μL saline (Sigma, Cat. No. S8776) or 20 μL saline (control group) intranasally (in) three times per week for 11 weeks. This model induces class switching of B cells into IgE-producing plasma cells in secondary lymphoid organs and promotes accumulation of IgE plasma cells in the bone marrow. Eight weeks after the first HDM administration, subcutaneous injections of 25 mg / kg REGN1103 (anti-IL-4Rα) or 25 mg / kg isotype control were initiated in some mice, continuing until the end of the experiment. At week 11, two doses of REGN5459 (anti-BCMA × anti-CD3) or two doses of isotype control antibody were administered subcutaneously, and mice were rested in the absence of intranasal HDM for 9 weeks. Details of the HDM exposure and antibody treatment protocol are outlined in Table 1 and Figure 1.

[0128] [Table 1]

[0129] One and six weeks after the last dose of HDM, approximately 100 μL of blood was collected from all groups of mice by retro-orbital bleeding and transferred to microtainer tubes (BD, Cat. No. 365967) for serum isolation. Total IgE concentrations in serum were determined using an OptEIA™ ELISA kit (BD Biosciences, #555248) according to the manufacturer's instructions. Briefly, ELISA plates were coated overnight at 4° with IgE capture antibody diluted in coating buffer (carbonate-bicarbonate buffer, Sigma; Cat. No. C3041, diluted in 100 mL distilled water, Gibco; Cat. No. 15230-270). The coated plates were washed four times with washing buffer (0.05% Tween 20 diluted in DPBS, GE; Cat. No. SH3001304, Sigma; Cat. No. P1379). Plates were blocked with Assay Diluent (BD; Cat. No. 555213) for 1 h at room temperature (RT). 100 μL of serum samples diluted in 3-fold serial dilutions starting at 1:50 or 1:100 and IgE standards diluted in 2-fold serial dilutions starting at 100 ng / mL were added to the plate and incubated for 2 h at RT. Plates were then washed 4 times with wash buffer and incubated in 100 μL of working detection solution (detection antibody with sAv-HRP) for 1 h at RT. Plates were washed 7 times, soaked in wash buffer for 5 min, and washed again 4 times to remove unbound detection antibody. 100 μL of TMB substrate solution (BD; Cat. No. 555214) was added to each sample and the plate was incubated in the dark for 30 min, after which 50 μL of stop solution (2N sulfuric acid, BDH VWR analytical; Cat. No. BDH7500) was added. Absorbance was measured at 450 nm and IgE concentrations were calculated from a standard curve. Serum IgE values ​​are shown as ng / mL. Statistical significance was determined by Kruskal-Wallis test with Dunn's post hoc multiple comparison test in GraphPad Prism.

[0130] result In a chronic HDM model, anti-IL4Rα treatment by itself reduced but did not eliminate circulating IgE (FIGS. 2A and 2B; Table 2).

[0131] [Table 2]

[0132] Anti-BCMA x anti-CD3 treatment alone transiently reduced IgE production, but serum IgE levels recovered after 6 weeks of rest (Figures 2A and 2B; Table 2). The combination of anti-IL-4Rα and anti-BCMA x anti-CD3 treatment eliminated serum IgE (undetectable by IgE ELISA) (Figures 2A and 2B; Table 2), demonstrating the efficacy of blocking IL-4Rα and depleting plasma cells with anti-BCMA x anti-CD3 as a successful strategy to block IgE production. EXAMPLES

[0133] Therapeutic combination of BCMAxCD3 bispecific and anti-IL-4Rα antibodies completely blocks HDM-specific IgE production during ongoing HDM exposure This example demonstrates that blocking IL-4R and depleting plasma cells is effective in blocking allergen-specific IgE production, even in the presence of continued allergen exposure.

[0134] The IL-4 / IL-13 pathway inhibitor used in this example was the mouse anti-IL-4R antibody REGN1103, which is a mouse surrogate antibody of the human monoclonal antibody against the human IL-4R identified as REGN668 (also known as dupilumab). REGN1103 is described in Example 1 above. The plasma cell depleting agent used was the anti-BCMA x anti-CD3 bispecific antibody REGN5459, described in Example 1 above. A mouse IgG1 antibody (REGN1094) and a human IgG4 x anti-CD3 antibody (REGN4460) were used as isotype controls.

[0135] material and method To determine the effect of anti-IL-4Rα and anti-BCMA × anti-CD3 combinations on IgE production in a relevant in vivo model, a chronic Dermatophagoides dust mite (HDM)-induced pulmonary inflammation study was performed in mice homozygous for human BCMA and human CD3 instead of mouse BCMA and CD3. Chronic pulmonary inflammation and sustained IgE production were induced by exposing mice to 25 μg HDM (Greer, Cat. No. XPB70D3A25) diluted in 20 μL saline (Sigma, Cat. No. S8776) or 20 μL saline (control group) administered intranasally (in) three times per week for 19 weeks. This model induces class switching of B cells into IgE-producing plasma cells in secondary lymphoid organs and promotes accumulation of IgE plasma cells in the bone marrow. Twelve weeks after the first HDM administration, subcutaneous injections of 25 mg / kg REGN1103 (anti-IL-4Rα) or 25 mg / kg REGN1094 (isotype control) were initiated in some mice, which continued until the end of the experiment. At week 15, two doses of REGN5459 (anti-BCMA × anti-CD3) or two doses of REGN4460 (isotype control) were administered subcutaneously, and mice were exposed to HDM for an additional 4 weeks. Details of the HDM exposure and antibody treatment protocol are shown below in Table 3 and Figure 3.

[0136] [Table 3]

[0137] At 1, 3, and 5 weeks after administration of REGN5459, Approximately 100 μL of blood was collected from all groups of mice and transferred to microtainer tubes (BD, Cat. No. 365967) for serum isolation. HDM-specific IgE concentrations in serum were determined using a Mouse Serum Anti-HDM IgE Antibody Assay Kit (Chondrex Cat. No. 3037) according to the manufacturer's instructions. Briefly, 100 μL of serum samples diluted at 1:20 or 1:60 and HDM-IgE standards diluted to a starting concentration of 50 ng / mL and further diluted 2-fold serially were added to pre-coated plates provided with the kit and incubated overnight at 4°C. The plates were then washed 3 times with wash buffer and incubated in 100 μL of biotinylated HDM provided with the kit. The plates were then washed 4 times with wash buffer and incubated in 100 μL of streptavidin peroxidase (provided with the kit) for 30 min at RT. Plates were washed seven times, 100 μL of TMB substrate solution (provided in the kit) was added to each sample, and plates were incubated in the dark for 25 min before adding 50 μL of stop solution (2N sulfuric acid, provided in the kit). Absorbance was measured at 450 nm, and HDM-IgE concentrations were calculated from the standard curve. Serum IgE values ​​are shown as ng / mL. The lower limit of quantification (LLOQ) of the ELISA for HDM-specific IgE was 15.62 ng / mL. Statistical significance was determined in GraphPad Prism by Kruskal-Wallis test with Dunn's post hoc multiple comparison test.

[0138] result In the chronic HDM model, anti-IL4Rα treatment showed a trend toward a reduction in serum HDM-specific IgE levels, although it did not reach statistical significance, and this trend was maintained across the three time points examined (see Figures 4A, 4B, and 4C and Table 4). Anti-BCMA x anti-CD3 treatment alone led to a significant reduction in circulating HDM-specific IgE compared to the isotype control group one week after REGN5459 administration (Figure 4A), but this effect was short-lived, and 3 or 5 weeks after bispecific antibody administration, the levels of HDM-specific IgE were not significantly different compared to the isotype control group (Figures 4B and 4C and Table 4). The combination of anti-IL-4Rα and anti-BCMA x anti-CD3 treatment eliminated serum HDM-specific IgE (not detectable by ELISA). This effect was maintained for the duration of the experiment (see Figures 4A, 4B, and 4C and Table 4), demonstrating the efficacy of blocking IL-4Rα and depleting plasma cells with anti-BCMA x anti-CD3 as a successful strategy to block allergen-specific IgE production, even in the presence of continued allergen exposure.

[0139] [Table 4] EXAMPLES

[0140] Effect of combined BCMA×CD3 bispecific antibody and anti-IL-4Rα antibody treatment on IgE bone marrow plasma cells Mice described in Example 2 were also analyzed for IgE bone marrow plasma cells. Following the HDM exposure and antibody treatment protocols described in Table 3 and Figure 3, mice were sacrificed and femurs harvested from the mice. Bone marrow was extracted from the femurs by cutting both ends of each bone, placing each bone in an individual well of a 96-well PCR plate with holes drilled in the bottom of each well, then placing the PCR plate on top of a 96-well 2 mL deep well collection plate and centrifuging the plate at 500g for 4 minutes. The bone marrow was resuspended in 0.5 mL of RBC lysis buffer and incubated at room temperature for 3 minutes, after which 1-2 mL of PBS was added to quench the lysis buffer. The cells were centrifuged at 400g for 4 minutes, the supernatant was decanted, and the pellet was resuspended in 1 ml of DPBS and filtered through a Millipore plate filter (100 μm) into a 2 mL deep well plate. The cells were then centrifuged and resuspended in 200 μL of PBS. Next, the cells were centrifuged and resuspended in 200 μL of PBS. Next, bone marrow cells were plated in 96-well plates and stained for live / dead cell markers followed by antibody staining with antibodies B220, CD138, IgM, IgG1, IgA, IgD, IgE (extracellular block), and "Dump" (including TCRβ, CD200R3, Ly6G, CD49b, and CD11b).

[0141] After staining, cells were washed twice with MACS buffer and fixed with BD Cytofix (cat. no. 554655) diluted 1:4 in PBS for 15 min, then resuspended in MACS buffer and stored at 4°C. On the day of acquisition, cells were washed, incubated in BD Perm / Wash buffer (cat. no. 554723) for 10 min, and stained with intracellular antibodies Light Chain κ, IgG1, and Intra IgE. Cells were then acquired on an LSRFortessa instrument and analyzed using FlowJo software. Mature IgE bone marrow plasma cells were identified as Live, Dump- B220- Light Chain κ+ IgE+. Percent reduction of plasma cells in individual antibody-treated mice was calculated with the following formula: 100-(100 x percent plasma cells / mean percent plasma cells of isotype group), where percent plasma cells are calculated relative to total live cells.

[0142] result In a chronic HDM model with continued HDM exposure after antibody treatment, neither anti-IL4Rα nor BCMA×CD3 treatment alone had a significant effect on IgE bone marrow plasma cells at the time of harvest (5 weeks after BCMA×CD3 treatment), although treatment with anti-IL4Rα showed a trend towards reduced IgE bone marrow plasma cells (see Figure 5 and Table 5). In contrast, the combination of continuous anti-IL4Rα treatment with transient anti-BCMA×anti-CD3 treatment resulted in a significant reduction in IgE bone marrow plasma cells compared to both untreated and isotype controls (see Figure 5 and Table 5).

[0143] [Table 5] EXAMPLES

[0144] Effect of combined BCMA×CD3 bispecific antibody and anti-IL-4Rα antibody treatment on IgE production and IgE-producing cells To determine the effect of combined treatment with anti-IL-4Rα and anti-BCMA x anti-CD3 on IgE production and IgE-producing cells in a relevant in vivo model, an HDM-induced pulmonary inflammation study was performed in mice homozygous for human BCMA and human CD3 instead of mouse BCMA and CD3 as described above in Examples 1-2. Mice were exposed to 25 μg HDM diluted in 20 μL saline or 20 μL saline (control group) administered intranasally (in) three times per week for 15 weeks. By immunizing mice with HDM, we induced chronic lung inflammation and persistent IgE production. This model induces class switching of B cells in secondary lymphoid organs to IgE-producing plasma cells and promotes accumulation of IgE plasma cells in the bone marrow. At 12 weeks after the first HDM administration, subcutaneous injections of 25 mg / kg REGN1103 (anti-IL-4Rα) or 25 mg / kg REGN1094 (isotype control) were started in some mice for the remainder of the experiment. At 15 weeks, two doses of REGN5459 (anti-BCMA × anti-CD3) or two doses of REGN4460 (isotype control) were administered subcutaneously and the mice were allowed to rest for 2 weeks without further HDM administration. Details of the HDM exposure and antibody treatment protocol are outlined below in Figure 6 and Table 6.

[0145] [Table 6]

[0146] Following HDM exposure and antibody treatment protocols, mice were sacrificed and blood, spleens, and bones were harvested. Blood was collected from all groups of mice by cardiac puncture and transferred to microtainer tubes (BD, catalog no. 365967) for serum isolation. HDM-specific IgE concentrations in serum were determined using a Mouse Serum Anti-HDM IgE Antibody Assay Kit (Chondrex catalog no. 3037) according to the manufacturer's instructions. Briefly, 100 μL of serum samples diluted at 1:10 or 1:60 and HDM-IgE standards diluted to a starting concentration of 50 ng / mL and further diluted two-fold serially were added to pre-coated plates provided with the kit and incubated overnight at 4 °C. Plates were then washed three times with wash buffer and incubated in 100 μL of biotinylated HDM provided with the kit. The plate was then washed 4 times with wash buffer and incubated in 100 μL of streptavidin peroxidase (provided in the kit) for 30 min at RT. The plate was washed 7 times and 100 μL of TMB substrate solution (provided in the kit) was added to each sample and the plate was incubated in the dark. After incubation at 4°C for 25 min, 50 μL of stop solution (2N sulfuric acid, provided in the kit) was added. Absorbance was measured at 450 nm and HDM-IgE concentrations were calculated from the standard curve. Serum IgE values ​​are shown as ng / mL. Statistical significance was determined in GraphPad Prism by Kruskal-Wallis test with Dunn's post hoc multiple comparison test.

[0147] Spleens and femurs were also harvested from mice. Spleens were mashed over a 74 micron cell strainer in 2 mL of RPMI medium using the rear end of a 3 mL syringe, and a suspension of single cells was transferred to a 96-well plate. Bone marrow was extracted from femurs by cutting both ends of each bone, placing each bone into an individual well of a 96-well PCR plate with holes drilled in the bottom of each well, then placing the PCR plate on top of a 96-well 2 mL deep-well collection plate, and centrifuging the plate at 500 g for 4 min. Spleen samples were resuspended in 1 mL of RBC lysis buffer and bone marrow in 0.5 mL of RBC lysis buffer, incubated at room temperature for 3 min, and then 1–2 mL of PBS was added to quench the lysis buffer. Cells were centrifuged at 400 g for 4 min, the supernatant was decanted, and the pellet was resuspended in 1 mL of DPBS and filtered through a Millipore plate filter (100 μm) into a 2 mL deep-well plate. The cells were then centrifuged and the spleen cells were resuspended in 1 mL of PBS and the bone marrow in 200 μL of PBS. One-tenth of the spleen cells and all the bone marrow cells were then plated in a 96-well plate and stained for live / dead cell markers followed by antibody staining with antibodies B220, CD138, IgM, IgG1, IgA, IgD, IgE (extracellular block), and "Dump" (including TCRβ, CD200R3, Ly6G, CD49b, and CD11b). After staining, the cells were washed twice with MACS buffer, fixed for 15 minutes with BD Cytofix (cat. no. 554655) diluted 1:4 in PBS, resuspended in MACS buffer and stored at 4 degrees. On the day of acquisition, the cells were washed and incubated for 10 minutes in BD Perm / Wash Buffer (cat. no. 554723) and stained with intracellular antibodies Light Chain κ, IgG1, and Intra IgE. Cells were then acquired on an LSRFortessa instrument and analyzed using FlowJo software. Mature plasma cells were identified as Live, Dump- (Dump contains TCRb, CD200R3, Ly6G, CD49b and CD11b) B220- Light Chain k+. Percent reduction of plasma cells in individual antibody-treated mice was calculated as: 100-(100 x percent plasma cells / mean percent plasma cells of isotype group).Here, the percent plasma cells are calculated relative to the total viable cells. The results are shown in Table 7 below.

[0148] result In the chronic HDM model, anti-IL4Rα treatment (group F) showed a trend towards reduced serum HDM-specific IgE levels, although most samples had detectable levels of HDM-specific IgE (see Table 7 and Figure 7). Both anti-BCMA x anti-CD3 treatment alone (group E) and the combination of anti-IL-4Rα and anti-BCMA x anti-CD3 treatment (group G) eliminated serum HDM-specific IgE, with all mice showing levels below the lower limit of quantification. These data demonstrate that anti-BCMA x anti-CD3 treatment is sufficient to significantly reduce serum HDM-specific IgE at 2 weeks post-treatment.

[0149] In the same experiment, anti-IL4Rα treatment did not affect total bone marrow plasma cells (Figure 8A) but showed a trend towards IgE bone marrow plasma cell reduction (Figure 8B). Anti-BCMA × anti-CD3 treatment alone led to a significant reduction in both total and IgE bone marrow plasma cells at the time of harvest (2 weeks after REGN5459 administration) compared to both the untreated and isotype control treated groups (Figures 8A-8B). The combination of anti-IL-4Rα and anti-BCMA × anti-CD3 treatment also significantly reduced total and IgE-specific bone marrow plasma cells to the same extent as anti-BCMA × anti-CD3 alone, demonstrating that the latter treatment is sufficient to deplete bone marrow plasma cells. Similar results were observed in the spleen; anti-IL4Rα treatment did not significantly reduce total or IgE splenic plasma cells. Anti-BCMA × anti-CD3 treatment alone led to a significant reduction in total splenic plasma cells at the time of harvest (2 weeks after REGN5459 administration) compared to both the untreated and isotype control-treated groups (Figures 8C-8D). The combination of anti-IL-4Rα and anti-BCMA × anti-CD3 treatment also significantly reduced total splenic plasma cells to the same extent as anti-BCMA × anti-CD3 alone, demonstrating that the latter treatment was sufficient to deplete splenic plasma cells. IgE plasma cells were reduced by both anti-BCMA × anti-CD3 treatment alone and the combination of anti-IL-4Rα and anti-BCMA × anti-CD3. However, the reduction in IgE splenic plasma cells only achieved statistical significance when compared to the group that received HDM for 12 weeks in the absence of antibody treatment or the isotype control group, and did not achieve statistical significance when compared to the group that received HDM for 15 weeks and no antibody treatment.

[0150] [Table 7]

[0151] [Table 8]

[0152] The present invention should not be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

Claims

1. a pharmaceutical composition for use in a method for reducing or eliminating allergen-specific serum IgE in a subject, the pharmaceutical composition comprising an IL-4 / IL-13 pathway inhibitor, wherein the IL-4 / IL-13 pathway inhibitor is an anti-IL-4 / IL-13 bispecific antibody or an IL-4 receptor (IL-4R) antibody; The subject has an allergic disease or disorder, a mast cell activation disorder, or mastocytosis; The method includes administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor together with a therapeutically effective amount of a plasma cell depleting agent; The pharmaceutical composition, wherein the plasma cell depleting agent is an anti-BCMA / anti-CD3 bispecific antibody or antigen-binding fragment thereof comprising: (a) a first antigen-binding domain that specifically binds to BCMA; and (b) a second antigen-binding domain that specifically binds to CD3.

2. a pharmaceutical composition for use in a method for treating allergy or preventing or reducing the severity of an allergic response to an allergen, the pharmaceutical composition comprising an IL-4 / IL-13 pathway inhibitor, the IL-4 / IL-13 pathway inhibitor being an anti-IL-4 / IL-13 bispecific antibody or an IL-4R antibody; The subject has an allergic disease or disorder, a mast cell activation disorder, or mastocytosis; The method comprises administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor together with a therapeutically effective amount of a plasma cell depleting agent, wherein the plasma cell depleting agent is an anti-BCMA / anti-CD3 bispecific antibody or antigen-binding fragment thereof comprising: (a) a first antigen-binding domain that specifically binds to BCMA; and (b) a second antigen-binding domain that specifically binds to CD3.

3. 1. A pharmaceutical composition for use in a method for treating allergy or for preventing or reducing the severity of an allergic reaction to an allergen, the pharmaceutical composition comprising a plasma cell depleting agent, the plasma cell depleting agent comprising: (a) a first antigen binding molecule that specifically binds to BCMA; and (b) a second antigen-binding domain that specifically binds to CD3; or an anti-BCMA / anti-CD3 bispecific antibody or antigen-binding fragment thereof; the subject has an allergic disease or disorder, a mast cell activation disorder, or mastocytosis and is receiving a background treatment regimen including one or more doses of an IL-4 / IL-13 pathway inhibitor, wherein the IL-4 / IL-13 pathway inhibitor is an anti-IL-4 / IL-13 bispecific antibody or an IL-4R antibody; The method comprises administering to the subject at least one dose of the pharmaceutical composition comprising the plasma cell depleting agent.

4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the allergic disease or disorder is selected from the group consisting of allergic asthma, hay fever, chronic urticaria, food allergy, pollen allergy, and allergy caused by a non-food allergen.

5. The pharmaceutical composition according to any one of claims 1 to 4, wherein the subject is at risk of anaphylaxis caused by an allergen.

6. The pharmaceutical composition according to any one of claims 1 to 5, wherein the subject has seasonal allergies.

7. The pharmaceutical composition according to any one of claims 1 to 6, wherein the subject has a severe allergy.

8. The pharmaceutical composition according to any one of claims 1 to 7, wherein the subject has a food allergy.

9. 9. The pharmaceutical composition of claim 8, wherein the plant allergen is contained in or derived from a food selected from the group consisting of milk, dairy products, eggs, celery, sesame, wheat, meat, fruit, soy, fish, shellfish, sugar, peanuts, legumes, and tree nuts.

10. 9. The pharmaceutical composition of any one of claims 1 to 8, wherein the subject has an allergy to a non-food allergen, and the non-food allergen is selected from the group consisting of dust, dust mites, pollen, insect venom, mold, animal fur, animal dander, wool, latex, ragweed, grass, and birch.

11. a pharmaceutical composition for use in a method for increasing the efficacy and / or tolerability of an immunotherapeutic regimen in an allergic subject, the pharmaceutical composition comprising an IL-4 / IL-13 pathway inhibitor, the IL-4 / IL-13 pathway inhibitor being an anti-IL-4 / IL-13 bispecific antibody or an IL-4R antibody; The method comprises administering to the subject, prior to or concurrently with the immunotherapy regimen, a pharmaceutical composition comprising an IL-4 / IL-13 pathway inhibitor together with a therapeutically effective amount of a plasma cell depleting agent, wherein the plasma cell depleting agent is an anti-BCMA / anti-CD3 bispecific antibody or antigen-binding fragment thereof, comprising: (a) a first antigen-binding domain that specifically binds BCMA; and (b) a second antigen-binding domain that specifically binds CD3.

12. The pharmaceutical composition of claim 11 , wherein the immunotherapy is oral immunotherapy.

13. The pharmaceutical composition of claim 11 , wherein the immunotherapy is subcutaneous immunotherapy.

14. The pharmaceutical composition according to any one of claims 11 to 13, wherein the subject has a food allergy.

15. These include milk, dairy products, eggs, celery, sesame, wheat, meat, fruit, soybeans, fish, shellfish, and sand.

15. The pharmaceutical composition of claim 14, wherein the patient has an allergy to sugar, peanuts, legumes, or tree nuts.

16. 14. The pharmaceutical composition of any one of claims 11 to 13, wherein the subject is allergic to a non-food allergen selected from the group consisting of dust, dust mites, pollen, insect venom, mold, animal fur, animal dander, wool, latex, ragweed, grass, and birch.

17. The pharmaceutical composition of any one of claims 11 to 16, wherein the plasma cell depleting agent is administered prior to the initiation of an immunotherapeutic regimen.

18. The pharmaceutical composition of any one of claims 11 to 17, wherein at least one dose of the IL-4 / IL-13 pathway inhibitor is administered prior to the initiation of the immunotherapeutic regimen.

19. The pharmaceutical composition of any one of claims 11 to 18, wherein the IL-4 / IL-13 pathway inhibitor is administered simultaneously with an immunotherapy regimen.

20. The pharmaceutical composition of any one of claims 1 to 19, wherein the IL-4 / IL-13 pathway inhibitor is an anti-IL-4 / IL-13 bispecific antibody.

21. The pharmaceutical composition according to any one of claims 1 to 19, wherein the IL-4 / IL-13 pathway inhibitor is an anti-IL-4R antibody.

22. The pharmaceutical composition of claim 21, wherein the anti-IL-4R antibody comprises a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:

2.

23. 23. The pharmaceutical composition of claim 22, wherein the anti-IL-4R antibody comprises a heavy chain and a light chain, the heavy chain having the amino acid sequence of SEQ ID NO: 9 and the light chain having the amino acid sequence of SEQ ID NO:

10.

24. The pharmaceutical composition of any one of claims 1 to 23, wherein the IL-4 / IL-13 pathway inhibitor is dupilumab.

25. Anti-BCMA / anti-CD3 bispecific antibodies (a) a first antigen-binding domain comprising an HCVR comprising the amino acid sequence of SEQ ID NO: 12 and an LCVR comprising the amino acid sequence of SEQ ID NO: 20; (b) a second antigen-binding domain comprising an HCVR comprising the amino acid sequence of SEQ ID NO: 28 and an LCVR comprising the amino acid sequence of SEQ ID NO:

20.

26. Anti-BCMA / anti-CD3 bispecific antibodies (a) a first antigen-binding domain comprising an HCVR comprising the amino acid sequence of SEQ ID NO: 12 and an LCVR comprising the amino acid sequence of SEQ ID NO: 20; (b) a second antigen-binding domain comprising an HCVR comprising the amino acid sequence of SEQ ID NO: 36 and an LCVR comprising the amino acid sequence of SEQ ID NO:

20.

27. The pharmaceutical composition of any one of claims 1 to 26, wherein the IL-4 / IL-13 pathway inhibitor is administered before the plasma cell depleting agent.

28. IL-4 / IL-13 pathway inhibitor is administered after the plasma cell depleting agent, claims 1-2 7. The pharmaceutical composition according to any one of claims 6 to 6.

29. The pharmaceutical composition of any one of claims 1 to 26, wherein the IL-4 / IL-13 pathway inhibitor and the plasma cell depleting agent are administered simultaneously.

Images